[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"OHSU Knight Cancer Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":581},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,43,65,86,110,132,152,173,214,237,259,290,311,332,349,371,390,411,432,453,473,495,517,539,561],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053521","phase-2-induction-and-consolidation-with-fludarabine-cytarabine-idarubicin-and-venetoclax-for-the-treatment-of-acute-myeloid-leukemia-100053521",false,"NCT07228273","Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","A Phase II Randomized Clinical Trial of Venetoclax Combined With FLAG IDA Induction and Consolidation Compared to Standard of Care for Newly Diagnosed Patients With Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Ability to comprehend the investigational nature of the study and provide written informed consent\n* Age 18 to ≤ 65 years (yrs), at the time of consent\n* All gender identities, races, or ethnicities are eligible\n* Newly documented, previously untreated diagnosis of AML or myelodysplastic syndrome (MDS) with marrow blasts ≥ 10%, in agreement with 2022 European LeukemiaNet criteria (ELN22)\n\n  * Leukapheresis and treatment with cytarabine or hydroxyurea prior to study initiation is permitted for cytoreduction in patients with proliferative disease. NOTE: Treatment with cytarabine is limited to up to 2 grams total at least 14 days prior to starting on protocol defined therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Willingness to undergo hematopoietic stem cell transplant (HSCT)\n* Ability to take medications by mouth or feeding tube\n* Adequate hematologic and organ function\n* Institutional standards, New York Heart Association (NYHA) criteria for cardiac function\n* Calculated creatinine clearance (according to the Cockcroft-Gault equation) \\> 40 mL\u002Fmin\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) ≤ 3 x upper limit of normal (ULN), unless considered due to leukemic involvement\n* Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 x ULN, unless considered due to leukemic involvement\n* Total bilirubin ≤ 1.5 x ULN, unless due to Gilbert's disease or leukemic involvement\n* Willing and able to\n\n  * Adhere to study schedule of activities and lifestyle restrictions while on treatment;\n  * Provide bone marrow (BM) aspirate and core biopsy samples; AND\n  * Accept supportive and prophylactic care for hematologic toxicities, infection, and immediate sequelae, including transfusions\n* Negative pregnancy test within 3 days of start of treatment for persons of childbearing potential (PCBP)\n* Based on animal studies and the known pharmacology of the study drugs, PCBP and sperm-producing participants who are sexually active with a PCBP must comply with study requirements for contraception\n\n  * PCBP (participants and PCBP partners of participants) must agree to use an approved contraception and to refrain from donating \u002F cryopreserving ova from cycle (C) 1 day (D) 1 until 6 months following the last dose of study treatment\n  * Participants who produce viable sperm and who have intercourse with PCBP must agree to use an approved contraception method and to refrain from donating sperm from C1D1 until 3 months following the last dose of study treatment\n\nExclusion Criteria:\n\n* Documented t(15;17) (acute promyelocytic leukemia \\[APL\\]), and\u002For mutation(s) to FLT3 ITD or core binding factor (CBF). Point mutations within the tyrosine kinase domain (FLT3 TKD) are allowed\n* Another active malignancy within the previous 5 years, except treated early stage carcinomas of the skin, or at the investigator's discretion\n* Known, active central nervous system (CNS) involvement with AML\n* Recent and significant medical interventions, such as major surgery within 28 days of start of treatment\n* GVHD or autologous stem cell transplant within 100 days of start of treatment\n* Currently receiving investigational therapy or chemotherapy within 28 days, or 5 half-lives, whichever is longer, with the exception of hydroxyurea or cytarabine for cytoreduction purposes\n* Prior treatment with a BCL 2 inhibitor within 12 months prior to the start of treatment\n* Use of strong or moderate CYP3A4 inducers or inhibitors or P-gp inhibitors within 2 days or 3 half-lives, whichever is longer, prior to start of treatment with venetoclax or at the discretion of the investigator if dose reductions, based on the interaction, have been specified\n* History of allergic response to any of the interventional agents or any excipients in the formulations\n* Inadequate organ function, including the following (or at the discretion of the investigator):\n\n  * History of New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) \\\u003C 40% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan\n  * Unstable\u002Funcontrolled angina pectoris, history of severe and\u002For uncontrolled ventricular arrhythmias, or history of myocardial infarction within the last 6 months\n  * A white blood cell count (WBC) \\> 25 x 10\\^⁹\u002FL\n* Known dysphagia in the absence of a feeding tube, short-gut syndrome, or other conditions or causes that would affect the ingestion and\u002For gastrointestinal absorption of drugs administered orally\n* Active hepatic disorder or documented positive hepatitis B or C virus (HBV\u002FHCV, respectively) status, except in cases of undetectable HBV\u002FHCV viral load for at least 3 months prior to the start of treatment. (Hepatitis B or C testing is not required for eligibility assessment.)\n* Individuals with positive serology for human immunodeficiency virus (HIV) who are undergoing treatment with highly active antiretroviral therapy (HAART) (or another therapy that may interfere with metabolism of study agents) are not eligible. If the HIV infection is controlled with another medication type or if an acceptable alternative HIV treatment can be substituted for HAART, enrollment may proceed\n* Uncontrolled infection. Participants with controlled infection must be afebrile and hemodynamically stable for at least 72 hours prior to start of treatment and must be amenable to alternate treatment if current treatment will interact with investigational regimen\n* Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Unwillingness to stop breastfeeding. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding is not allowed throughout the study for 6 weeks after the last dose of study drug","ALL","18 Years","65 Years",{"count":21,"type":22},102,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.",[28,29],"Acute Myeloid Leukemia","Myelodysplastic Syndrome","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2025-12-12",{"date":38,"type":22},"2029-08-24",{"name":40,"class":41},"OHSU Knight Cancer Institute","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100543539","phase-1-iadademstat-in-combination-with-azacitidine-and-venetoclax-in-treating-newly-diagnosed-acute-myeloid-leukemia-100543539","NCT06357182","Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia","A Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination With Azacitidine and Venetoclax in Newly Diagnosed AML","Inclusion Criteria:\n\n* Patients at least 18 years of age will be considered for inclusion without bias against gender identity, race, or ethnicity\n* Ability to comprehend the investigational nature of the study and provide written informed consent\n* Patients with previously untreated, morphologically documented AML based on World Health Organization (WHO) 2008 definitions who are ineligible for standard of care (SOC) intensive chemotherapy (IC) induction OR documented unwillingness to undergo IC induction. Ineligible for IC is defined as:\n\n  * Documented intermediate- or adverse-risk AML based on European Leukemia Network (ELN) 2022 criteria\n  * Note: Cases of AML (MDS) overlap with 10-19% bone marrow (BM) or peripheral blood (PB) blasts will be considered\n  * Note: Cases of acute promyelocytic leukemia (PML) and AML with BCR::ABL1 fusions will be excluded\n* Eastern Cooperative Oncology Group (ECOG) performance ≤ 2 (Patients aged ≥ 75 years, at the time of consent)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Patients aged ≥ 75 years, at the time of consent)\n\n  * High total bilirubin values may require indirect and direct bilirubin testing. Individuals with known Gilbert's syndrome may be considered for enrollment despite high indirect (and total) bilirubin\n* Creatinine clearance (CrCl) of ≥ 60 mL\u002Fmin (estimated using the Cockcroft Gault formula or measured by 24 hours urine collection. If altered, CrCl is determined to be related to concomitant medication that alters renal function\n* Patients aged ≥ 18 to 74 years (ECOG performance status \\[PS\\] ≤ 3 is accepted) at consent must meet ≥ 1 of the following criteria defining a co morbidity:\n\n  * ECOG PS of 2 or 3 (Note: Patients ≥ 18 to 74 years of age with PS of 0-1 must meet criteria of one of the following comorbidities.)\n  * Cardiac history of congestive heart failure (CHF) requiring treatment or ejection fraction ≤ 50% or chronic stable angina\n  * Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume in 1 second (FEV1) ≤ 65%\n  * CrCl ≥ 30 mL\u002Fmin to \\\u003C 45 ml\u002Fmin\n  * Moderate hepatic impairment with total bilirubin \\> 1.5 to ≤ 3.0 × ULN;\n\n    * High total bilirubin values may require indirect and direct bilirubin testing. Individuals with known Gilbert's syndrome may be considered for enrollment despite high indirect (and total) bilirubin\n  * Other comorbidities that the physician judges to be incompatible with intensive chemotherapy (IC). In these cases, the comorbidity must be reviewed and approved by the principal investigator (PI) before study enrollment\n* Ability to swallow oral medications\n* No ongoing anticoagulation or antiplatelet therapy within 14 days of start of treatment with IADA\n* No history of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention\n* No history of stroke or intracranial hemorrhage within 180 days of start of IADA\n* No major bleeding event, as defined by the International Society of Thrombosis and Hemostasis (ISTH), within 12 weeks of start of IADA\n* Uncorrected international normalized ratio (INR) or activated partial thromboplastin time (aPTT) of \\\u003C 1.5 x ULN.\n\n  * If INR or aPTT \\> 1.5 x ULN has been corrected (prior to enrollment), then history of disseminated intravascular coagulation (DIC) must be absent\n* White blood cell (WBC) \\\u003C 20 x 10\\^9\u002FL prior to study start. Cytoreduction prior to study treatment is allowed with\n\n  * Hydroxyurea for up to 14 days and until 24 hours prior to start of IADA; or\n  * Leukapheresis for up to 14 days prior to start of IADA\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) ≤ 2.0 x institutional ULN\n\n  * Lower hepatic function may be considered if liver enzyme abnormalities are determined by the treating MD and principal investigator (PI) to be due to leukemic infiltration\n* Willing and able to\n\n  * Adhere to study schedule of activities and life style restrictions while on treatment;\n  * Provide bone marrow (BM) aspirate and core biopsy samples; and\n  * Accept supportive and prophylactic care for hematologic toxicities, infection, and immediate sequelae, including transfusions\n* Negative pregnancy test within 72 hours of start of IADA for persons of childbearing potential (PCBP)\n* Willingness to comply with study requirements for contraception, as follows: PCBP and sperm-producing participants who are sexually active with a PCBP must use study approved contraception from start of investigational product (first dose of IADA) until 6 months after the last dose of IADA. Pregnancy is exclusionary because the agents used in this study have the potential for teratogenic or abortifacient effects\n\nExclusion Criteria:\n\n* Prior allergic response to iadademstat (IADA), venetoclax, azacitidine, or any excipients in the formulations\n* Body weight \\\u003C 50 kg\n* Investigational therapy within 5 half-lives or, if unknown, within 28 days prior to start of IADA\n* Treatment for AML within 14 days prior to start of IADA. Cytoreduction for patients with proliferative disease must meet the criteria listed in inclusion criteria\n* Radiotherapy less than 14 days prior to start of IADA\n* Recent and significant medical interventions, such as major surgery within 28 days prior to the start of IADA, or stem cell transplant within 100 days prior to the start of IADA. Patients with active treatment for graft-versus-host disease (GVHD) are excluded\n* Another active malignancy within 5 years prior to the start of IADA, or at the investigator's discretion\n* Treatments targeting or inhibiting LSD1\u002FKDM1A or BCL 2 within 12 months prior to the start of IADA\n* Documented dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally\n* Treatment with monoamine oxidase inhibitors (e.g., tranylcypromine), if treatment is not finalized at least 3 weeks prior to the start of IADA\n* Active central nervous system involvement with AML\n* Uncontrolled infection. Participants with controlled infection must be afebrile and hemodynamically stable for at least 72 hours prior to start of IADA and must be amenable to alternate treatment if current treatment will interact with investigational regimen\n* Active hepatic disorder or documented positive hepatitis B or C virus (HBV\u002FHCV, respectively) status, except in cases of undetectable HBV\u002FHCV viral load for at least 3 months prior to the start of IADA. (Hepatitis B or C testing is not required for eligibility assessment.)\n* Individuals serology positive for human immunodeficiency virus (HIV) and under active treatment with highly active antiretroviral therapy (HAART) (or another therapy that may interfere with metabolism of study agents). Otherwise, enrollment may be considered in cases of HIV that is controlled with another treatment type or in cases that that acceptable modification of the patient's HIV treatment exists\n* Use a P-gp inhibitor within 21 days or 3 half-lives whichever is longer prior to treatment with venetoclax\n* Use of strong or moderate CYP3A4 inducers or inhibitors within 2 days or 3 half lives whichever is longer, prior to start of treatment with venetoclax\n* Unwillingness to stop breastfeeding. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided throughout the study and until at least 60 days after last dose of IADA\n* Uncontrolled hypertension (i.e., systolic blood pressure \\> 180 mm Hg, diastolic blood pressure \\> 95 mm Hg). Use of anti-hypertensive agents to control hypertension before C1D1 is allowed\n* Patients with poorly controlled diabetes. Poorly controlled diabetes mellitus defined as glycosylated hemoglobin (HbA1c) ≥ 8%; patients with a history of transient glucose intolerance due to corticosteroid administration may be enrolled in this study if all other inclusion\u002Fexclusion criteria are met\n* Patients with mean of triplicate corrected QT interval (Fridericia's correction formula \\[QTcF\\]) \\> 450 ms at Screening based on central reading\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active uncontrolled infection, unstable cardiac or pulmonary function or acute insufficiency (e.g., symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia), or psychiatric illness or social situation that could limit compliance with study requirements, at the discretion of the investigator",{"count":51,"type":22},30,[53],"PHASE1","This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may lead to inhibition of cell growth in LSD1-overexpressing cancer cells. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving iadademstat with azacitidine and venetoclax may be safe, tolerable and\u002For effective in treating patients with newly diagnosed AML who cannot undergo intensive chemotherapy.",[28,56],"Myelodysplastic Syndrome\u002FAcute Myeloid Leukemia","2026-06-28",{"date":59,"type":34},"2026-06-30",{"date":61,"type":34},"2024-08-22",{"date":63,"type":22},"2028-05-29",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":42},"100584908","phase-2-intrathecal-cytarabine-methotrexate-and-hydrocortisone-for-the-prevention-of-high-grade-chimeric-antigen-receptor-t-cell-associated-neurotoxicity-syndrome-100584908","NCT06895473","Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","A Phase 2 Study of Prophylactic IT Chemotherapy to Prevent High-Grade Chimeric Antigen Receptor (CAR) T-Cell-Associated Neurotoxicity Syndrome","Inclusion Criteria:\n\n* Written informed consent. Participant or legally authorized representative (LAR) must provide written informed consent prior to any study-specific procedures or interventions\n* Age ≥ 18 years. All genders, races, and ethnic groups will be included\n* Must be receiving SOC Yescarta® or Tecartus® in the inpatient setting\n* Agree to adhere to institutional guidelines for contraception during the first 30 days post CAR-T\n\n  * Rationale for eligibility criteria based on contraception and pregnancy (both participants and partners of a sperm-producing participant): It shall be known to all participants that the effects of CAR-T or IT chemotherapy on the developing human fetus are unknown. For this reason, persons of reproductive potential must agree to use adequate contraception. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Platelet count \\> 50,000\u002Fmm\\^3 (μL)\n* Adequate coagulation tests including international normalized ratio (INR) \\\u003C 1.6 and fibrinogen \\> 100\n\nExclusion Criteria:\n\n* Active\u002Fconcurrent diagnosis of any central nervous system (CNS) hematologic malignancy\n\n  * History or presence of CNS disorder such as poorly controlled seizure disorder (seizure within the 12 months), transverse myelitis, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement\n* Known history of hypersensitivity to IT chemotherapy\n* Subject has a contraindication to LP including:\n\n  * Presence of a posterior fossa mass\n  * Skin infection near puncture site\n  * Uncorrected bleeding diathesis\n  * Suspicion of increased intracranial pressure\n  * Acute spinal cord trauma\n* Subject is receiving an antiplatelet and\u002For anticoagulant that cannot be held prior to LP according to best available evidence\n* Known bleeding disorders\n* Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgement, make the participant inappropriate for study participation or would put the participant at risk",{"count":73,"type":22},26,[25],"This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal \\[IT\\]) works in preventing high-grade immune effector-associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy. ICANS is a challenging complication of CAR T-cell therapy that causes neurological effects varying from mild headaches or temporary confusion to hallucinations, swelling in the brain, and seizures. Between 20%-70% of patients receiving CAR T-cell therapy show symptoms of neurotoxicity.",[77],"Hematopoietic and Lymphatic System Neoplasm","2026-06-24",{"date":80,"type":34},"2026-06-26",{"date":82,"type":34},"2025-06-04",{"date":84,"type":22},"2027-12-31",{"name":40,"class":41},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":109},"100470538","improving-decision-making-encounters-in-lung-cancer-using-a-low-literacy-conversation-tool-100470538","NCT05407168","Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool","Improving Decision-Making Encounters in Lung Cancer (I DECide) II: A Randomized Control Trial Of A Low-Literacy Conversation Tool","iDECIDE","Inclusion Criteria:\n\n* AIM 1: Suspected lung cancer\n* AIM 1: English fluency\n* AIM 1: \\> 6-month life expectancy\n* AIM 1: Score of ≥ 3 on the cognitive impairment screener\n* AIM 2 PARTICIPANTS: Participation in Aim 1\n* AIM 2 CLINICIANS: Discussing lung cancer treatment decisions with Aim 1 participants","99 Years",{"count":96,"type":22},300,[98],"NA","This clinical trial evaluates the effectiveness of a conversation tool on patient-centered health and decision-making outcomes in patients with lung cancer making treatment decisions. This research is being conducted to help doctors understand the information patients need to participate in shared decision-making about their lung cancer treatment options. The focus of this research is to study how patients choose lung cancer treatment options and the information needed to make that choice, with a focus on patients with lower health literacy.",[101],"Lung Carcinoma","2026-06-22",{"date":104,"type":34},"2026-06-25",{"date":106,"type":34},"2022-10-31",{"date":84,"type":22},{"name":40,"class":41},4,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":42},"100644123","peer-support-program-for-improving-quality-of-life-among-head-and-neck-patients-connecting-through-cancer-trial-100644123","NCT07664241","Peer Support Program for Improving Quality of Life Among Head and Neck Patients, Connecting Through Cancer Trial","Connecting Through Cancer: Feasibility of a Peer Support Program for Head and Neck Patients","Inclusion Criteria:\n\n* MENTEE GROUP: Ability to understand and the willingness to sign a written informed consent document\n* MENTEE GROUP: Willingness to have mentor-mentee interactions with the mentor selected by Imerman Angels (documented as part of informed consent)\n* MENTEE GROUP: Age 18 or older at the time of consent (upper age limit 89)\n* MENTEE GROUP: Diagnosed with head \\& neck cancer (all stages) and planning to receive, currently receiving or recently completed (within 12 months) active treatment OR in follow-up and reporting unmet social\u002Fsupport needs\n* MENTEE GROUP: English-speaker\n* MENTEE GROUP: Access to electronic device that can be used for communication\n* MENTEE GROUP: Eastern Cooperative Oncology Group (ECOG) score less than or equal to 2\n* CAREGIVER GROUP: Ability to understand and the willingness to sign a written informed consent document\n* CAREGIVER GROUP: Age 18 or older at the time of consent (upper age limit 89)\n* CAREGIVER GROUP: Caregiver of patient diagnosed with head and neck cancer who is also enrolled in the study\n* CAREGIVER GROUP: English-speaker\n* CAREGIVER GROUP: Access to electronic device that can be used for communication\n\nExclusion Criteria:\n\n* MENTEE GROUP: Mentee must not be regularly engaging in other support programs at the start of the study intervention\n* MENTEE GROUP: Undergoing active professional treatment for cognitive or emotional difficulties or neurological deficits that preclude adherence to the study protocol\n* MENTEE GROUP: Any other social, emotional, or personal situation that will preclude adherence to the study protocol, at the discretion of the investigator\n* CAREGIVER GROUP: Caregivers must not be regularly engaging in other support programs at the start of the study intervention\n* CAREGIVER GROUP: Undergoing active professional treatment for cognitive or emotional difficulties or neurological deficits that preclude adherence to the study protocol\n* CAREGIVER GROUP: Any other social, emotional, or personal situation that will preclude adherence to the study protocol, at the discretion of the investigator",true,"89 Years",{"count":120,"type":22},56,[98],"This clinical trial tests whether a peer support program is feasible for head and neck cancer patients. Social support at the time of diagnosis has been shown to improve head and neck cancer quality of life before and after treatment. However, not all patients have a strong social support system. Recent research has shown that peer support programs have the potential to address unmet social support needs among cancer patients. These programs involve cancer survivors (peer mentors) providing emotional and informational support to cancer patients (mentees) earlier in their disease course. Peer support programs may also reduce caregiver burden by providing an additional source of support for the patient. A one-on-one peer support program may be feasible for patients with head and neck and their caregivers.",[124],"Malignant Head and Neck Neoplasm","NOT_YET_RECRUITING","2026-06-18",{"date":78,"type":34},{"date":129,"type":22},"2026-07-01",{"date":84,"type":22},{"name":40,"class":41},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100641614","feasibility-of-an-enhanced-symptom-monitoring-and-expedited-subspecialty-care-referral-intervention-to-improve-side-effect-management-for-patients-with-melanoma-receiving-an-immune-checkpoint-inhibitor-100641614","NCT07660666","Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor","EMPOWER: Enhancing Melanoma Care Through Patient-Reported Outcomes Monitoring With Early, Rapid Immunotherapy Toxicity Subspecialty Care","Inclusion Criteria:\n\n* PATIENT: Age 18 years or older\n* PATIENT: Histologically confirmed diagnosis of melanoma\n* PATIENT: Plan to begin a standard of care (SOC) immune checkpoint inhibitor (ICI) for the treatment of melanoma per Food and Drug Administration (FDA) approval and\u002For National Comprehensive Cancer Network (NCCN) guidelines\n* PATIENT: Willing and able to provide informed consent\n* CAREGIVER: Age 18 years or older\n* CAREGIVER: Family member or primary caregiver of a study participant\n\nExclusion Criteria:\n\n* PATIENT: Previously received ICI therapy\n* PATIENT: Life expectancy of \\\u003C 6 months at time of enrollment\n* PATIENT: Concurrently receiving a non-ICI systemic therapy\n* PATIENT: Concurrently receiving radiation, unless hypofractionated palliative radiation prescribed to alleviate poorly controlled symptoms (e.g., pain)\n* PATIENT: Needs to rely on a proxy to complete patient-reported outcome instruments\n* PATIENT: Unwilling or unable to complete surveys electronically\n* CAREGIVER: Needs to rely on a proxy to complete survey instrument(s)\n* CAREGIVER: Unwilling or unable to complete surveys electronically",{"count":140,"type":22},50,[98],"This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune checkpoint inhibitor. Immune checkpoint inhibitors have improved outcomes for patients with advanced melanoma, but their use is frequently complicated by immune related adverse events (irAEs). IrAEs can affect any organ system, range in severity from mild to life threatening, and often require a pause or stopping of immunotherapy treatment. Early identification and management of irAEs may reduce progression to severe toxicity. Electronic patient self reporting of symptoms with ways to support early involvement of non oncology subspecialists may be a feasible way to improve side effect management for patients with melanoma receiving an immune checkpoint inhibitor.",[144],"Melanoma","2026-06-16",{"date":102,"type":34},{"date":148,"type":22},"2026-11-01",{"date":150,"type":22},"2029-06-01",{"name":40,"class":41},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":42},"100642600","a-tailored-web-based-program-compass-to-improve-exercise-and-dietary-changes-in-stage-i-iii-pancreatic-cancer-patients-receiving-neoadjuvant-chemotherapy-100642600","NCT07651358","A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy","Community for Physical Activity and Supportive Nutrition Strategies (COMPASS)","Inclusion Criteria:\n\n* Age 18 years or older on date of enrollment\n\n  * Confirmed by review of the date of birth as documented in the electronic medical record (EMR) and subsequently recorded in a case report form (CRF)\n* Diagnosed with stage I-III pancreatic cancer\n\n  * Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm\n* Scheduled to receive neoadjuvant chemotherapy at Oregon Health \\& Science University (OHSU)\n\n  * Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm\n* Willing to adhere to the study protocol\n\n  * Confirmed verbally with the participant and response documented in the Participant Tracking database\n\nExclusion Criteria:\n\n* Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent\n\n  * In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigators, Dr. Kerri Winters-Stone and\u002For Dr. Jackilen Shannon\n* A medical condition, movement or neurological disorder, or medication use that contraindicates participation in light intensity exercise\n\n  * Confirmed by a combination of reviewing the EMR, and self-report during the initial screening call. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone or Dr. Jackilen Shannon, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible\n* Not fluent in English and therefore incapable of answer survey questions, reading the intervention web portal, and providing informed consent in English\n\n  * Confirmed verbally with the participant and response documented in the Participant Tracking database",{"count":51,"type":22},[98],"This clinical trial studies whether a tailored, web-based program (web portal), Community for Physical Activity and Supportive Nutrition Strategies (COMPASS), can be used to improve exercise and dietary changes in patients with stage I-III pancreatic cancer who are receiving chemotherapy before surgery (neoadjuvant). Pancreatic cancer is a rare and understudied cancer, particularly in the area of promoting a healthy lifestyle to preserve physical and mental well-being during a long and difficult treatment regimen. Since pancreatic cancer is rare, programs have limited resources available to reach the patients who could benefit from programs aimed at promoting exercise and a healthy diet. The COMPASS web-portal is easily accessed by the patient via a computer, tablet, or phone. It is tailored to the unique needs of pancreatic cancer patients and provides exercise and diet recommendations along with behavioral support as they undergo the long process of cancer therapy. This may be a more effective way to reach and engage with the patient, which may improve exercise and dietary changes in stage I-III pancreatic cancer patients receiving neoadjuvant chemotherapy.",[163,164,165],"Stage I Pancreatic Cancer AJCC v8","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","2026-06-12",{"date":145,"type":34},{"date":169,"type":34},"2026-04-15",{"date":171,"type":22},"2027-06-30",{"name":40,"class":41},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":42},"100624088","phase-4-morning-versus-afternoon-administration-of-immunotherapy-for-the-treatment-of-advanced-or-metastatic-solid-tumors-the-knight-shift-study-100624088","NCT07405086","Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","Knight Cancer Institute Study of Histology-Agnostic Immunotherapy With Focus on Timing: - Knight SHIFT - A Prospective, Multi-Histology Pragmatic Study","Inclusion Criteria:\n\n* Must provide written informed consent before any study-specific procedures or interventions are performed\n* Aged ≥ 18 years\n* Histologically confirmed advanced\u002Fmetastatic solid tumor as follows:\n\n  * Non small cell lung cancer (NSCLC) (driver-negative, immune checkpoint inhibitor \\[ICI\\]-eligible)\n  * Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (platinum-eligible),\n  * Renal cell carcinoma (RCC)\n  * Biliary-tract cancer (BTC)\n  * Hepatocellular carcinoma (HCC)\n  * Melanoma\n* Planned to receive a Food and Drug Administration (FDA)-approved immune check point inhibitor (e.g., anti-PD-1, anti-PD-L1, anti-CTLA4) regimen for the treatment of their malignancy\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n\nExclusion Criteria:\n\n* Prior ICI-based regimen for treatment of cancer\n* Current or prior use of immunosuppressive medication within 28 days before planned standard-of-care immunotherapy infusion, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses not exceeding 10 mg\u002Fday of prednisone (or equivalent corticosteroid)\n* Uncontrolled autoimmune disease requiring immunosuppression\n* Active, uncontrolled central nervous system (CNS) metastases",{"count":181,"type":22},160,[183],"PHASE4","This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Circadian rhythm refers to the internal biological clock in which various processes in the body, including immune cell activity, are controlled by the time of day. Exactly how this works is not fully understood, and the researchers want to see if circadian rhythm control of the immune system can influence response to immunotherapy based on whether it is given in the morning (before 11:00 am) or afternoon (12:00pm). The time of day that immunotherapy is given (morning versus afternoon) may impact the effectiveness in treating patients with advanced or metastatic solid tumors.",[186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206],"Advanced Biliary Tract Carcinoma","Advanced Head and Neck Squamous Cell Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Lung Non-Small Cell Carcinoma","Advanced Malignant Solid Neoplasm","Advanced Melanoma","Advanced Renal Cell Carcinoma","Metastatic Biliary Tract Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hepatocellular Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Renal Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","2026-06-10",{"date":166,"type":34},{"date":210,"type":34},"2026-06-08",{"date":212,"type":22},"2028-12-31",{"name":40,"class":41},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":42},"100403111","phase-2-177lu-dotatate-for-the-treatment-of-stage-iv-or-recurrent-breast-cancer-100403111","NCT04529044","177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","A Phase II Pilot Study of (Lutetium (177Lu)-DOTATATE in Patients With Metastatic Breast Cancer","Inclusion Criteria:\n\n* Life expectancy of \\> 6 months, as determined by the investigator\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients aged \\>= 18-100 years old at time of informed consent\n* Histologically or cytologically confirmed metastatic breast carcinoma\n* Stage IV or recurrent disease with distant metastases\n* Female and male patients with breast cancer will be included in the study\n* Participants must have experienced disease progression after at least two lines of standard treatment modalities and\u002For one prior line of cytotoxic chemotherapy (not just endocrine therapy). Specifically, patients must have received or declined the following therapies: a) Hormone receptor positive (HR+)\u002FHER2: endocrine therapy and CDK4\u002F6 inhibitor (i); b) HER2+: trastuzumab, pertuzumab, T-DM1 and tucatinib; c) Triple negative breast cancer (TNBC): chemotherapy, immunotherapy (in PD-L1+ tumors). Patients can be consented if they are foregoing treatments known to confer survival advantage\n* Participants must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v1).1 that is amendable to biopsy\n* Confirmed presence of SSTR based on \\> 50% of lesions with DOTATATE uptake of 68Ga DOTATATE equivalent to the liver\n* Participants must have fully recovered from the acute toxic effects of all prior treatment to grade 1 or less, except alopecia and =\\\u003C grade 2 neuropathy which are allowed\n* Participant must have Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2\n* Participant must consent to undergo a pre-treatment screening biopsy for enrollment\n* Hemoglobin \\>= 8.0 g\u002FdL with no blood transfusion in the past 28 days (measured within 28 days prior to administration of study treatment)\n* Absolute neutrophil count (ANC) \\>= 2.0 x 10\\^9\u002FL (measured within 28 days prior to administration of study treatment)\n* Platelet count \\>= 75 x 10\\^9\u002FL (measured within 28 days prior to administration of study treatment)\n* Total bilirubin =\\\u003C 3 x institutional upper limit of normal (ULN) (measured within 28 days prior to administration of study treatment)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) =\\\u003C 2.5 x institutional upper limit of normal (unless liver metastases are present in which case they must be =\\\u003C 5 x ULN) (measured within 28 days prior to administration of study treatment)\n* Serum albumin \\>= 3.0 g\u002FL, unless prothrombin time or international normalized ratio (INR) value is within the normal range (measured within 28 days prior to administration of study treatment)\n* Participants must have serum creatinine =\\\u003C 1.7 mg\u002FdL, or creatinine clearance estimated of \\>= 51 mL\u002Fmin using the Cockcroft-Gault equation or based on a 24 hour urine test (measured within 28 days prior to administration of study treatment)\n* Female participants of childbearing potential (FOCBP) must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* FOCBP agree to use a highly-effective method of contraception starting with the first dose of study therapy up to 7 months after the last dose of study therapy\n\n  * FOCBP are those who are not proven postmenopausal. Postmenopausal is defined as:\n\n    * Amenorrheic for \\> 24 consecutive months following cessation of exogenous hormonal treatments\n    * Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50 years of age\n    * Radiation-induced oophorectomy with last menses \\> 1 year ago\n    * Chemotherapy-induced menopause with \\> 1 year interval since last menses\n    * Surgical sterilization (bilateral oophorectomy or hysterectomy or tubal ligation)\n\nExclusion Criteria:\n\n* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of first dose of 177Lu- DOTATATE treatment\n\n  * Individuals in the follow-up phase of a prior investigational study may participate as long as it has been 4 weeks since last dose of the previous investigational agent or device\n* Prior external beam radiation therapy to more than 25% of the bone marrow\n* Other malignancy unless curatively treated with no evidence of disease for \\>= 5 years except: adequately treated non-melanoma skin cancer or curatively treated in situ cancer of the cervix\n* Known brain metastases, unless these metastases have been treated and stabilized\n* Peptide receptor radionuclide therapy at any time prior to study enrollment\n* Known hypersensitivity to somatostatin analogues or any component of the 68Ga- DOTATATE or 177Lu- DOTATATE formulations\n* Patients with uncontrolled infection will not be enrolled until infection is treated per provider discretion\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure\n* Uncontrolled diabetes mellitus as defined by a fasting blood glucose \\> 2x ULN\n* Any patient receiving treatment with short-acting somatostatin analogs, which cannot be interrupted for both 24 hours before and after the administration of 177Lu, or any patient receiving treatment with long-acting release somatostatin analogs that cannot be interrupted for at least 4 weeks before the administration of 177Lu- DOTATATE\n* Any surgery or radiofrequency ablation within 12 weeks prior to enrollment in the study; or prior radioembolization; chemoembolization; or external beam radiation therapy (EBRT) to \\> 25% of bone marrow, at any time\n* Any chemotherapy or targeted therapy within 4 weeks prior to enrollment in the study\n* Current spontaneous urinary incontinence making impossible the safe administration of the radioactive study agent\n* Any psychiatric illness that prevents patient from informed consent process\n* Any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol\n* Participant is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment","100 Years",{"count":223,"type":22},10,[25],"This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2. 177Lu-DOTATATE is a targeted therapy that uses DOTATATE, linked to a radioactive agent called 177Lu. DOTATATE attaches to tumor cells with SSTR2 and delivers 177Lu to kill them. Giving 177Lu-DOTATATE may help decrease the number and size of tumors and the number of circulating cancer stem cells in patient's blood for the treatment of patients with breast cancer positive for SSTR2.",[227,228,229],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma","2026-06-03",{"date":232,"type":34},"2026-06-05",{"date":59,"type":22},{"date":235,"type":22},"2027-12-20",{"name":40,"class":41},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":258},"100567815","narrow-excision-versus-wide-excision-for-the-treatment-of-adults-with-invasive-cutaneous-melanoma-iceman-trial-100567815","NCT06673095","Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial","ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Narrow Excision Versus Wide Excision for Adults With Primary Invasive Cutaneous Melanomas","Inclusion Criteria:\n\n* Participants or legally authorized representatives (LAR) must provide written informed consent before any study-specific procedures or interventions are performed\n* Age ≥ 18 years; all biological gender identities and racial\u002Fethnic groups will be included\n* Participants must have histologically confirmed primary cutaneous melanoma. Acral melanomas are eligible.\n* Participants must have one of the following:\n\n  * American Joint Committee on Cancer (AJCC) 8th Ed clinical stage IA disease with Breslow thickness \\> 0.5 mm AND at least one high-risk feature (Mitotic rate ≥ 2\u002Fmm2, age ≤ 42, lymphovascular invasion, head\u002Fneck location)\n  * AJCC 8th Ed Clinical Stage IB melanoma\n\n    * If a melanoma is widely transected and the true Breslow depth is uncertain, then to be eligible for this trial, the melanoma must be re-biopsied to ascertain an accurate Breslow depth.\n* The index melanoma must be classified as low risk on the Merlin Assay (SkylineDx)\n* Study intervention (surgery) must be completed within 120 days of the original diagnostic biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 50%)\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Participants with a history of HIV infection are eligible\n* Participants can speak, read and write in English or Spanish\n\nExclusion Criteria:\n\n* Uncertain diagnosis of melanoma (i.e. severely dysplastic nevi, melanocytic lesion of unknown malignant potential, atypical intraepidermal melanocytic proliferations)\n* The patient has already undergone wide local excision at the site of the primary index lesion\n* The patient has a pure desmoplastic melanoma. A pure desmoplastic melanoma is defined as being \\> 90% desmoplastic type. Melanomas with \\\u003C 90% desmoplastic type may be included in this trial\n* Mucosal and ocular melanomas are also excluded, as these are approached differently for surgical excision\n* Physical, clinical, radiographic, or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma\n* Participants with known or suspected cancer with regional or distant metastasis are excluded from this clinical trial because this trial is aimed at evaluating the control of localized disease\n* The patient has undergone surgery on a separate occasion to clear the lymph nodes of the probable draining lymphatic field, including a sentinel lymph node biopsy, of the index melanoma\n* Planned adjuvant radiotherapy to the primary melanoma site after excision\n* Participant is unwilling or unable to comply with study procedures",{"count":245,"type":22},1000,[98],"This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma. Currently the standard of care is to take wide margins (boarder of healthy tissue surrounding the melanoma) when removing melanoma. Narrow margin excision removes a smaller amount of healthy tissue when surgically removing the melanoma. Narrow margin excision may be effective in removing the melanoma while also reducing surgical complications and improving quality of life for adults with invasive cutaneous melanoma.",[249,250],"Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","2026-05-22",{"date":253,"type":34},"2026-05-27",{"date":255,"type":34},"2024-12-11",{"date":84,"type":22},{"name":40,"class":41},5,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":275,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":42},"100637528","phase-i-randomized-controlled-trial-of-functional-resistance-training-in-older-cancer-survivors-the-aces-trial-100637528","NCT07606313","Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial","ACES: Advancing Capacity to Integrate Exercise Into the Care of Older Cancer Survivors","ACES","Inclusion Criteria:\n\n* Age 65 years of age or older\n* Diagnosed with stage I-IV cancer =\\\u003C 5 years ago\n* Completed surgery, chemotherapy, or radiation therapy \\> 3 months ago (concurrent maintenance therapy, such as hormone therapy for breast or prostate cancer, is permissible)\n* Self-report at least one limitation in Activities of Daily Living (ADLs) OR at clinical risk of developing ADL impairment as evidenced by a 3-meter timed-up-and-go time \\> 13.5 seconds or 5-time chair stand time \\> 12 seconds\n* Able to ambulate independently; reliance on assistive devices other than a wheelchair is allowed\n* Currently underactive (an average of \\\u003C 30 minutes of moderate-vigorous intensity exercise 3 days\u002Fweek over the past four weeks)\n* Willing to be randomized into any of the three study arms and attend 80% or more of planned exercise sessions\n* Home internet sufficient for videoconferencing\n\nExclusion Criteria:\n\n* Contraindication to moderate intensity exercise\n* Health or medical condition that affects movement or neurological disorder, or medication that contraindicates participation in live remote resistance exercise\n* Cognitive impairment consistent with moderate dementia (confirmed by a Montreal Cognitive Assessment (MoCA) score \\\u003C 14). Cognitive impairment consistent with early-stage dementia (a MoCA score of \\\u003C20) unless a research partner (e.g., family member, caregiver, close friend) can also be consented and can assist in answering the survey questions, participating in the performance tests, or giving informed consent.\n* Not fluent in English and therefore incapable of answering survey questions, following directions during exercise or performance testing, and providing informed consent in English",{"count":268,"type":22},150,[98],"The study will assess the feasibility and preliminary efficacy of live, online supervised group functional resistance training in older cancer survivors who may have difficulty with independent functioning. The study design is a three-arm parallel group randomized controlled trial (immediate resistance training, delayed resistance training, stretching placebo) in 150 older cancer survivors. The resistance training program will be compared to two different types of common control groups: a stretching placebo group and a delayed intervention group. By using two control conditions, this study can also inform the design of future randomized trials on the selection of an appropriate control group.",[77,272,273,274],"Malignant Solid Neoplasm","Cancer","Functional Limitation",[273,276,277,278,279,280,281],"Exercise","Cancer survivor","Functional limitation","Clinical trial","Older adult","Feasibility","2026-05-21",{"date":284,"type":34},"2026-05-26",{"date":286,"type":22},"2026-05-18",{"date":288,"type":22},"2028-08-31",{"name":40,"class":41},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":42},"100521272","phase-2-amiodarone-for-the-prevention-of-atrial-fibrillation-after-minimally-invasive-esophagectomy-in-patients-with-esophageal-cancer-100521272","NCT06067438","Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer","A Prospective, Randomized Controlled Trial Evaluating the Efficacy of Amiodarone in the Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Minimally Invasive Esophagectomy","Inclusion Criteria:\n\n* All patients undergoing MIE will be evaluated for potential enrollment\n\n  * Indication of cancer, esophageal dysplasia or esophageal dysmotilities\n* Age \\> 18 years\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of chronic or paroxysmal AF, or atrial flutter\n* Previous severe adverse reaction or contraindication to amiodarone (e.g., pulmonary toxicity\u002Ffibrosis, hepatotoxicity, thyroid dysfunction)\n* Current preoperative use of amiodarone, as baseline home medication\n* Development of AF intraoperatively\n* Pregnancy\n\n  * Negative pregnancy tests are required for participants of childbearing potential (PCBP) on Day of Surgery (DOS)\n* Breastfeeding\u002Fchest feeding\n* Aborted MIE operation\n* QTcF (Fridericia formula) \\> 500 for heart rate (HR) 60-100 within 30 days\n\n  * For patients with a heart rate (HR) of between 50-59 on their pre-operative screening electrocardiography (EKG), we will first review evidence of chronotropic cardiac response to exercise before inclusion in the study. If a patient's HR increases to ≥ 100 with exercise, the patient is eligible for inclusion of study. Exercise testing options may include a stair climb, a brisk walk, or supine leg-lifts prior to surgery. If exercise is not an option, we can review results of formal stress testing chronotropic response (ie. HR ≥ 100). HR monitoring can be collected by either pulse oximeter or EKG",{"count":298,"type":22},90,[25],"This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients to receive preventative amiodarone or not. Further, there is no standard recommendation or guideline for preventative medications, such as amiodarone, to decrease the risk of AF in patients having MIE performed for cancer. In fact, most medical centers in the United States and around the world do not give preventative amiodarone after esophagectomy. Giving amiodarone after MIE surgery may be able to reduce the risk of AF for patients with esophageal cancer.",[302,303],"Atrial Fibrillation","Esophageal Carcinoma","2026-05-20",{"date":251,"type":34},{"date":307,"type":34},"2024-06-21",{"date":309,"type":22},"2027-08-30",{"name":40,"class":41},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":42},"100516973","internet-based-lifestyle-intervention-to-eradicate-obese-frailty-in-prostate-cancer-survivors-ilive-100516973","NCT06011499","Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE","Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE)","iLIVE","Inclusion Criteria:\n\n* INTERVENTION PARTICIPANTS: Age 18 or older\n* INTERVENTION PARTICIPANTS: Diagnosed with histologically confirmed prostate cancer\n* INTERVENTION PARTICIPANTS: Received \\>= 6 months of ADT any time in the past 10 years\n* INTERVENTION PARTICIPANTS: Completed radiotherapy, chemotherapy and\u002For surgery \\> 6 weeks prior to\n* INTERVENTION PARTICIPANTS: No intent to start adjuvant chemotherapy or radiotherapy within 6 months of enrollment\n* INTERVENTION PARTICIPANTS: Overweight or obese (body mass index \\> 25 kg\u002Fm2 to BMI ≤ 50).\n* INTERVENTION PARTICIPANTS: Evidence of frailty by meeting three or more of the following frailty criteria: weakness, slowness, fatigue, inactivity, and\u002For illness\n* INTERVENTION PARTICIPANTS: Not currently engaging in structured diet or resistance strength training exercise program\n* INTERVENTION PARTICIPANTS: Willing to be randomized into either study arm and adhere to study protocol\n* INTERVENTION PARTICIPANTS: Home internet sufficient for videoconferencing\n* INTERVENTION PARTICIPANTS: Signed informed consent\n* IMPLEMENTATION PARTICIPANTS: Be a key stakeholder (i.e., healthcare provider or administrative, or intervention participant \\[completers, partial completers, or no participation\\])\n* IMPLEMENTATION PARTICIPANTS: Verbal informed consent following receipt of an information sheet\n\nExclusion Criteria:\n\n* INTERVENTION PARTICIPANTS: Unintentional weight loss \\> 5% within the last year\n* INTERVENTION PARTICIPANTS: Contraindication to moderate intensity exercise\n* INTERVENTION PARTICIPANTS: Health or medical condition that affects weight status\u002Fbody composition (e.g., Cushing's syndrome, uncontrolled hyper-\u002Fhypo- thyroidism)\n* INTERVENTION PARTICIPANTS: Active malignancy (other than non-melanoma skin cancer)\n* INTERVENTION PARTICIPANTS: Not fluent in English and therefore incapable of answer survey questions, following directions during exercise or performance testing, and providing informed consent in English\n* INTERVENTION PARTICIPANTS: Currently taking or have taken creatine supplement in the month preceding baseline creatine testing",{"count":320,"type":22},250,[98],"This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.",[324],"Prostate Carcinoma","2026-05-06",{"date":327,"type":34},"2026-05-08",{"date":329,"type":34},"2024-03-12",{"date":84,"type":22},{"name":40,"class":41},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":338,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":348,"locationsCount":42},"100631757","get-fit-together-testing-a-socially-enhanced-exercise-program-in-older-men-with-prostate-cancer-100631757","NCT07504835","GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer","Inclusion Criteria:\n\n* Age 65 years of age or older.\n* Diagnosed with histologically confirmed prostate cancer.\n* Completed surgery, chemotherapy, radiation and\u002For systemic treatment (other than ADT) for cancer \\> 3 months ago.\n* Experiencing cancer loneliness.\n* Able to ambulate independently; reliance on assistive devices other than a wheelchair is allowed.\n* Willing to be randomized into any of the three study arms and attend 80% or more of planned exercise sessions.\n* Home internet sufficient for videoconferencing.\n\nExclusion Criteria:\n\n* Participating in regular group exercise and\u002For structured resistance training with other cancer survivors (\\> 1 exercise partner or groups of 3 or more).\n* Health or medical condition that affects movement or neurological disorder, or medication that contraindicates participation in live remote resistance exercise.\n* Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent.\n* Not fluent in English and therefore incapable of answer survey questions, following directions during exercise or performance testing, and providing informed consent in English.","MALE",{"count":268,"type":22},[98],"This clinical trial tests the impact of different levels of social support on the benefits of exercise in older men with prostate cancer. This trial compares a socially-enhanced supervised group exercise program to a supervised group exercise program with no social enhancement, and an unsupervised home-based program on cancer loneliness, social isolation, mental and physical health in older prostate cancer survivors. All study arms exercise for 6 months and outcomes are measured at baseline, 3 and 6 months. The primary outcome is cancer loneliness with secondary outcomes of mental and physical health.",[324],"2026-04-30",{"date":325,"type":34},{"date":169,"type":34},{"date":347,"type":22},"2029-06-30",{"name":40,"class":41},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":42},"100535235","phase-1-mosunetuzumab-with-chemotherapy-for-the-treatment-of-patients-with-untreated-c-myc-rearrangement-positive-high-grade-b-cell-lymphoma-or-diffuse-large-b-cell-lymphoma-100535235","NCT06249191","Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma","A Phase Ib\u002FII Study Evaluating the Safety and Efficacy of Mosunetuzumab in Combination With DA EPOCH in Previously Untreated C-Myc Rearrangement Positive High-Grade B Cell Lymphomas","Inclusion Criteria:\n\n* For both phases of the study, participant must be 18-75 years of age and have previously untreated high-grade B cell lymphoma (HGBCL) or diffuse large B cell lymphoma (DLBCL), including transformed DLBCL per the World Health Organization (WHO) 2022 classification, and with documented c-Myc rearrangement on fluorescence in situ hybridization (FISH) testing. Eligible types of c-Myc rearrangements will be performed by FISH testing and may include any single MYC rearrangement (single-hit lymphoma), Double hit (DHL) lymphoma or and triple hit (THL) lymphoma defined by translocations of MYC and BCL2 (DHL) and BCL6 (THL)\n* Pathology must be verified and confirmed by university pathologists at the enrolling institution and centrally (OHSU) for any biopsies read outside of either institution\n* Stage II or higher and International Prognostic Index (IPI) score of 2-5\n* Able to comply with the study protocol and procedures, in the investigator's judgment\n* At least one bi-dimensionally measurable nodal lesion, defined as ≥ 1.5 cm in its longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as ≥ 1.0 cm in its longest diameter\n* Confirmed availability of archival or freshly collected tumor tissue before study enrollment\n* Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2\n* Left ventricular ejection fraction (LVEF) defined by multiple-gated acquisition (MUGA) scan or echocardiogram (ECHO) within the institutional limits of normal\n* Absolute neutrophil count (ANC) ≥ 1.0 ×10\\^9\u002FL (14 days prior to first mosunetuzumab dose) (unless inadequate function is due to underlying disease, as established by extensive bone marrow involvement, or is due to hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator) without transfusion\n* Platelet count ≥ 75 ×10\\^9\u002FL (14 days prior to first mosunetuzumab dose) (unless inadequate function is due to underlying disease, as established by extensive bone marrow involvement, or is due to hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator) without transfusion\n* Total hemoglobin ≥ 10 g\u002FdL (21 days prior to first mosunetuzumab dose) (unless inadequate function is due to underlying disease, as established by extensive bone marrow involvement, or is due to hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator) without transfusion\n* Serum creatinine ≤ upper limit of normal (ULN); or estimated creatinine clearance ≥ 50 mL\u002Fmin by Cockcroft Gault method or other institutional standard methods, e.g. based on nuclear medicine renal scan\n* For persons of childbearing potential (PCBP), an agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \\\u003C 1% per year, and confirmed agreement to refrain from donating eggs, during the treatment period and for at least 3 months after the last dose of mosunetuzumab, and 3 months after the last dose of tocilizumab (if applicable), whichever is longer\n* For participants who can produce sperm and create pregnancy: confirmed agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm\n\nExclusion Criteria:\n\n* Pregnant or breast \u002Fchestfeeding\n* Prior treatment for DLBCL. Exceptions:\n\n  * Prednisone of ≤ 100 mg for up to 10 days, within 28 days prior to starting study treatment. Prednisone or equivalent corticosteroid must be discontinued by the time of treatment start\n  * One cycle of RCHOP or DA R EPOCH\n* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products\n* Contraindication to receive full dose of any of the individual components of EPOCH\n* Participants with history of confirmed progressive multifocal leukoencephalopathy (PML)\n* Known or suspected chronic active Epstein Barr virus (CAEBV) infection\n* Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \\[HBsAg\\] serology)\n\n  \\* Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is undetectable at the time of screening. These Participants must be willing to undergo monthly DNA testing and appropriate antiviral therapy as indicated\n* Acute or chronic hepatitis C virus (HCV) infection. Participants positive for HCV by antibody testing, but negative for HCV by polymerase chain reaction (PCR) are eligible\n* HIV seropositivity\n* Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study\n* Prior solid organ transplantation\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).\n* History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Exceptions:\n\n  * Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.\n  * Participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n  * Participants with a history of disease-related immune thrombocytopenic purpura, autoimmune hemolytic anemia, or other stable autoimmune diseases may be eligible after review and approval by the primary investigator (PI)\n* Systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of pre-phase treatment with prednisone up to 100 mg daily for 7 days (or equivalent corticosteroid dose) prior to cycle 1 day 1 (C1D1). Exceptions:\n\n  * The use of inhaled corticosteroids is permitted.\n  * The use of mineralocorticoids for management of orthostatic hypotension is permitted.\n  * The use of physiologic doses of corticosteroids for management of adrenal insufficiency is permitted\n* Current active central nervous system (CNS) involvement of lymphoma on the screening MRI brain\n* Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, neurodegenerative disease. Exceptions:\n\n  * Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits as judged by the investigator are allowed.\n  * Participants with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications are allowed in the expansion cohorts only\n* Prior radiotherapy to the mediastinal \u002F pericardial region within 4 weeks\n* Malignancy treated with curative intent unless in documented remission without treatment for 2 years prior to enrollment, or other malignancy that could affect compliance with the protocol or interpretation of results. Exception: Participants with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix are eligible. Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer is permitted\n* Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the Participant, including renal disease that would preclude chemotherapy administration or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)\n* Significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)\n* Significant cardiovascular disease, defined as\n\n  * New York Heart Association \\[NYHA\\] Class III or IV cardiac disease,\n  * Congestive heart failure,\n  * Myocardial infarction within the previous 6 months,\n  * Unstable arrhythmias, or\n  * Unstable angina\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks before C1D1\n* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis\n* Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \\> 2.5 x ULN within 14 days of initiation of study treatment\n* Total bilirubin ≥ 1.5 x ULN within 14 days of initiation of study treatment\n* International normalization ratio (INR) \\> 1.5 x ULN in the absence of therapeutic anticoagulation within 14 days of initiation of study treatment\n* Partial prothrombin time (PTT) or adjusted partial prothrombin time (aPTT) \\> 1.5 x ULN in the absence of a lupus anticoagulant within 14 days of initiation of study treatment\n* Herbal therapies intended as treatment of lymphoma\n* Medicinal or recreational cannabis products are not permitted while receiving the study intervention.","75 Years",{"count":51,"type":22},[53,25],"This phase Ib\u002FII clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as etoposide, doxorubicin, vincristine, cyclophosphamide and prednisone work in different ways to stop the growth of cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mosunetuzumab with chemotherapy may be safe, tolerable and\u002For effective in treating patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma.",[361,362],"Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma","2026-04-22",{"date":365,"type":34},"2026-04-24",{"date":367,"type":34},"2024-06-13",{"date":369,"type":22},"2027-04-01",{"name":40,"class":41},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":387,"leadSponsor":389,"locationsCount":42},"100635153","phase-1-ruxolitinib-with-azacitidine-maintenance-for-the-treatment-of-patients-with-acute-myeloid-leukemia-undergoing-reduced-intensity-allogeneic-stem-cell-transplantation-100635153","NCT07548983","Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation","A Phase I Study to Evaluate the Safety of Ruxolitinib in Combination With Azacitidine Maintenance in Patients Undergoing Reduced Intensity Allogeneic Transplant for Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\n* PART A: Willingness to provide written informed consent before any study-specific procedures or interventions are performed. For participants unable to independently provide consent, a legally authorized representative (LAR) must provide consent\n* PART A: Age ≥ 18 years, at the time of consent\n* PART A: All types and categories of AML, as defined by World Health Organization (WHO) 2022, excluding acute promyelocytic leukemia (APL)\n* PART A: In complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after induction of remission for transition to transplant by European LeukemiaNet 2022 Risk Stratification (ELN 2022)\n* PART A: Planned alloHSCT with granulocyte colony-stimulating factor mobilized peripheral blood stem cells (PBSCs) and pre transplant conditioning disease status assessment of CR or CRi, as defined by ELN 2022 criteria\n* PART A: Patient is at high risk for relapse based on cytogenetics, MRD by next generation sequencing (NGS), and\u002For ELN 2022 definition of adverse risk disease per the opinion of the treating physician\n* PART A: Patients must have an unrelated PBSC donor meeting study donor selection requirements\n* PART A: Only RIC or NMA conditioning must be plan and patient is not a candidate for myeloablative conditioning (MAC). Post-transplant cyclophosphamide \u002F tacrolimus \u002F mycophenolate mofetil (PTCy\u002FTac\u002FMMF) GVHD prophylaxis is planned with PTCy at 25 mg\u002Fkg\u002Fday on Day +3 and Day +4 post-HSCT\n\n  * Permitted conditioning regimens (per institutional protocol)\n\n    * Reduced-intensity conditioning:\n\n      * Fludarabine\u002F melphalan\n\n        * Dose reduction of melphalan to 100 rather than 140 are permitted at discretion of treating physician\n    * Non-Myeloablative Conditioning:\n\n      * Fludarabine\u002F busulfan\u002F total-body irradiation (TBI)\n      * Fludarabine\u002F TBI\n* PART A: Backup graft donor (meeting study donor selection requirements) identified and ready for cases of graft failure\n* PART A: Karnofsky performance status (KPS) ≥ 50%\n* PART A: Direct bilirubin ≤ 3 × upper limit of normal (ULN) within 7 days prior to start of conditioning. Patients with leukemic involvement or Gilbert's Syndrome must have a direct bilirubin of ≤ 2 x ULN within 7 days of start of conditioning\n* PART A: Creatinine clearance \\> 30 mL\u002Fmin, calculated by the Cockcroft-Gault formula or measured by 24-hour urine collection\n* PART A: Willingness to receive infusion of SOC blood products\n* PART A: Evidence of chronic hepatitis B virus (HBV) infection (i.e., hepatitis B virus surface antigen \\[HBsAg\\]-positive with undetectable or low HBV deoxyribonucleic acid \\[DNA\\]) in the absence of HBV therapy, or serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and hepatitis B virus core antibody \\[anti-HBc-positive\\]) is permitted but patient must agree to appropriate institutional guideline prophylaxis\n* PART A: History of hepatitis C virus (HCV) infection is permitted given prior curative treatment or undetectable HCV viral load by serology or polymerase chain reaction (PCR) testing\n\n  * Patients who are HCV antibody (Ab) seropositive but HCV ribonucleic acid (RNA) negative due to prior treatment or natural resolution are eligible\n* PART A: For persons of child-bearing potential (PCBP), a negative pregnancy test within ≤ 7 days of start of conditioning\n* PART A: Ruxolitinib may have adverse effects on a fetus in utero. Furthermore, it is not known if either drug agent has transient adverse effects on the composition of sperm. PCBP and participants who produce viable sperm must be willing to comply with study requirements for contraception starting at start of conditioning through 120 days after discontinuation of study treatment. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately\n* PART A: It is unknown whether ruxolitinib, or its metabolites, are excreted in human milk. Since many drugs are excreted in human milk, and because of the potential for serious adverse reactions in the nursing infant, patients must agree to not breast-feed for the entire 2 years of the study to be eligible for enrollment\n* PART B: Absolute neutrophil count (ANC) ≥ 1,000\u002FμL, measured twice approximately 48 hours apart, within 7 days prior to C2D1, in the absence of granulocyte colony-stimulating factor (G-CSF) treatment during this 7-day period\n* PART B: Platelet count ≥ 50,000\u002FμL, measured twice approximately 48 hours apart, within 7 days prior to C2D1, in the absence of platelet transfusions or growth factor therapies that increase platelet counts during this 7 day period\n* PART B: Hemoglobin \\> 8 g\u002FL within the 7 days prior to C2D1, regardless of transfusion support\n* PART B: Day +30 (+\u002F- 5 days) chimerism of ≥ 70% donor CD3+ cells and 100% donor CD33+ cells\n* PART B: For PCBP, a negative pregnancy test within 72 hours prior to C2D1\n* DONOR: Donor is willing and able to donate\n* DONOR: Unrelated donor with a 7\u002F8 or 8\u002F8 match at human leukocyte antigen (HLA)-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells\n* DONOR: Age 18-35 at the time of workup request for PBSC donation\n* DONOR: Meet the donor registries' medical suitability requirements for PBSC donation\n* DONOR: Must undergo screening, testing, and determination of eligibility according to current Food and Drug Administration (FDA) requirements as defined in 21 Code of Federal Regulations (CFR) 1271 Subpart C and applicable guidance documents. Donors will be tested using kits that are FDA licensed, approved, or cleared for human cell and tissue\u002Ftissue-product donor screening. Sample testing will be performed at Clinical Laboratory Improvement Amendments (CLIA) certified laboratories\n* DONOR: Must agree to donate PBSC\n* DONOR: Must have the ability to give informed consent according to standard (non study) informed consent according to applicable donor regulatory requirements\n\nExclusion Criteria:\n\n* PART A: Patients with active central nervous system (CNS) involvement with AML. Prior diagnosis of CNS involvement of AML will be allowed if curatively treated\n* PART A: Patients with malabsorption syndrome or other condition that precludes oral route of drug administration\n* PART A: Patients with prior intolerance to any of the interventional study drugs or component of the formulations\n* PART A: Patients with prior failure of treatment with ruxolitinib\n* PART A: Patients with history of any other malignancy within the 5 years prior to screening, with the exception of the following:\n\n  * Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;\n  * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\n  * Previous non-hematologic malignancy that has been successfully treated with curative intent (i.e., confined and surgically resected or treated with other modalities);\n  * Myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (only allowed if it transformed to AML and AML should be the indication for marrow transplantation)\n* PART A: Patients with ejection fraction (EF) \\\u003C 40% and patients with New York Heart Association (NYHA) grade III or IV heart failure\n* PART A: Patients with history of pulmonary embolism (PE) or myocardial infarction (MI) within the 6 months prior to cycle 1 day 1 (C1D1). Treated deep vein thromboses (DVTs) are allowed\n* PART A: Patients with known history of stroke (including intracranial hemorrhage) within 60 days prior to start of conditioning\n* PART A: Patients administered therapy with an investigational agent, a known JAK1\u002F2 inhibitor (with the exception of ruxolitinib), or a SOC anti-cancer therapy, including chemotherapy and radiotherapy, within 5 half lives prior to C1D1, or per institutional practice\n* PART A: Patients administered therapy with a biologic agent (e.g., a monoclonal antibody) for anti-neoplastic intent within 30 days prior to C1D1, or per the institutional practice\n* PART A: Patients with known clinically significant liver disease defined as ongoing drug-induced liver injury, alcoholic liver disease, non alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis\n* PART A: Patients with known human immunodeficiency virus (HIV) infection. HIV infection, even when controlled with combination antiretroviral therapy, is not allowed due to increased risk of lethal infections associated with marrow-suppressive therapy. Studies in participants under combination antiretroviral therapy may be undertaken at a later date\n* PART A: Patients with history of active tuberculosis (TB)\n* PART A: Patients with known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection\n\n  * Subjects with confirmed SARS-CoV-2 infection must be screen failed and may only rescreen after they meet institutional SARS-CoV-2 infection viral clearance criteria\n* PART A: Patients with evidence of clinically significant systemic infection\n* PART A: Patients with clinically significant coagulation abnormality defined by international normalized ratio (INR) \\> 1.5\n* PART A: Patients with recent significant medical interventions, such as major surgery within 28 days of C1D1. Standard of care procedures for patients with hematologic malignancies, such as biopsies and lumbar punctures, are allowed\n* PART A: Patients with psychiatric illness\u002Fsocial situation that would limit compliance with the study\n* PART A: Patients with history of clinically significant medical condition(s) (including comorbidities) and no other reason, per the determination of the investigator, which could interfere with the patient's adherence to the study protocol or would make the patient an unsuitable candidate to receive study drugs\n* PART B: Patients with evidence of primary graft failure (PGF) or secondary graft failure (SGF) while enrolled on Part A or SGF during screening for Part B\n* PART B: Patients who experienced a dose limiting toxicity (DLT) in Part A\n* PART B: Patients administered an investigational agent, a known JAK1\u002F2 inhibitor (with the exception of ruxolitinib), or SOC chemotherapy or radiotherapy within 5 half-lives of C2D1, or per institutional practice\n* PART B: Patients administered a biologic of anti-neoplastic intent within 30 days of C2D1, or per institutional practice\n* PART B: Patients with a plan for other maintenance therapy outside of this trial, including a FLT3-ITD inhibitor\n* PART B: Patients with evidence of clinically significant, uncontrolled systemic infection\n* PART B: Patients with Mount Sinai Acute Graft Versus Host Disease International Consortium (MAGIC) grade II or greater active aGVHD\n* PART B: Patients with ongoing or planned therapy with prednisone equivalent of ≥ 10 mg daily for GVHD treatment or other illness\n* PART B: Patients with newly diagnosed psychiatric illness or new social situation that would limit compliance with the study\n* PART B: Patients with new or recent history of clinically significant medical condition(s) (including comorbidities) or any other reason, per the determination of the investigator, which could interfere with the patient's adherence to the study protocol or would make the patient an unsuitable candidate to receive study drugs\n* DONOR: Recipient has evidence of donor-specific HLA antibody (DSA). If recipient is positive for HLA antibodies against a mismatched HLA in the selected donor, defined as the presence of DSA to any mismatched HLA allele\u002Fantigen at any of the following loci (HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5, -DQA1, - DQB1, -DPA1, -DPB1) with mean fluorescence intensity (MFI) \\> 3000 by microarray-based single antigen bead testing, the donor will be excluded. In patients receiving red blood cell or platelet transfusions, DSA evaluation should be performed prior to donor mobilization and initiation of recipient preparative regimen whenever possible\n* DONOR: Donors with positive coronavirus disease 2019 (COVID-19) testing results (confirmed by PCR) within 72 hours (hr) of stem cell collection",{"count":379,"type":22},40,[53],"This phase I trial studies the side effects and best dose of ruxolitinib (Rux) therapy alone (monotherapy) followed by Rux plus azacitidine (AZA) maintenance therapy and to see how well it works in treating patients with acute myeloid leukemia (AML) who are undergoing reduced intensity allogeneic hematopoietic stem cell transplantation (alloHSCT). AlloHSCT provides the only chance for cure for many patients with AML. AlloHSCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. This is often a sister or brother, but could be an unrelated donor. One of the common reasons for death after an alloHSCT is graft versus host disease (GVHD), which occurs when the transplanted cells from the donor attacks the recipient's normal cells. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat GVHD by blocking the signals of the cells that cause GVHD. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. Giving Rux after the transplant may stop GVHD from occurring. Maintenance therapy with AZA, may help prevent or delay cancer from coming back. Giving Rux monotherapy followed by Rux plus AZA maintenance therapy may be safe, tolerable, and\u002For effective in treating patients with AML who are undergoing alloHSCT.",[28],"2026-04-21",{"date":385,"type":34},"2026-04-23",{"date":304,"type":22},{"date":388,"type":22},"2028-12-29",{"name":40,"class":41},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":410},"100554851","phase-2-venetoclax-in-combination-with-cladribine-and-cytarabine-alternating-with-azacitidine-plus-venetoclax-for-the-treatment-of-newly-diagnosed-monocytic-aml-and-active-signaling-mutated-aml-100554851","NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML","A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine Alternating With Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML","Inclusion Criteria:\n\n* Ability to comprehend the investigational nature of the study and provide informed consent (i.e., participant or legally authorized representative \\[LAR\\]). Written informed consent must be obtained prior to any study-specific procedures or interventions\n\n  • Sign informed consent for the #4422 Biorepository prior to any study-specific procedures of interventions\n* Eligible AML patients of all races and ethnic groups will be considered for participation, irrespective of gender identity\n* Newly diagnosed, histologically confirmed monocytic AML, as defined by World Health Organization (WHO), or active signaling mutated AML defined as AML with mutation(s) to N\u002FKRAS, FLT3 ITD\u002FTKD, NF1, PTPN11 or CBL\n* Ineligible for standard of care induction therapy using intensive chemotherapy (IC) or unwilling to undergo IC induction therapy. Ineligible for IC is defined as\n\n  * ≥ 75 yrs of age; OR\n  * 18-74 yrs of age with one of the following:\n\n    * Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 2 at screening\n    * Severe cardiac disorder (e.g., congestive heart failure requiring treatment, ejection fraction ≤ 50%, or chronic stable angina)\n    * Severe pulmonary disorder (e.g., diffuse capacity of the lung for carbon monoxide \\[DLCO\\] ≤ 65% or forced expiratory volume in 1 second \\[FEV1\\] ≤ 65%)\n    * Creatinine clearance \\\u003C 45 ml\u002Fmin (calculated by the Cockcroft-Gault equation)\n    * Hepatic disorder with total bilirubin \\> 1.5 x upper limit of normal (ULN)\n    * Any other comorbidity that the treating physician judges to be incompatible with IC\n* If ≥ 75 yrs of age, the following organ function values must be met and ECOG must be 0 to 2 at screening:\n\n  * Creatinine clearance (calculated with the Cockcroft-Gault equation) ≥ 30 ml\u002Fmin\n  * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Unless due to leukemic infiltration)\n  * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) or alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 x ULN (Unless due to leukemic infiltration) (With the exception of documented Gilbert's syndrome or similar conditions. Liver function testing (LFT) and timepoints may be added, as clinically indicated, in such cases)\n\n    * Note: In cases of confirmed leukemic organ involvement, exceptions may be made\n* Willing and able to provide bone marrow (BM) samples, including BM samples for research use only analysis\n* Willing and able to accept supportive and prophylactic care for hematologic toxicities, infection, and immediate sequalae\n* Willingness to adhere to (a) study schedule of activities; (b) requirements for bio samples collections; and (b) lifestyle restrictions while on-treatment\n* Negative urine pregnancy test at screening and within 24 hours of cycle 1 day 1 (C1D1) for persons of childbearing potential (PCBP). Serum pregnancy testing will be used for confirmation in cases of equivocal results. Pregnancy is exclusionary because the agents used in this study have the potential for teratogenic or abortifacient effects\n* Willingness to comply with study requirements for contraception within the specified timeframe, as follows:\n\n  * Sperm producing participants who are active with PCBP must use approved contraception from C1D1 to 30 days, 3 months, or 6 months, after the last dose of venetoclax (30 days), azacitidine (3 months), cladribine (6 months), or cytarabine (6 months), whichever is later in time\n  * PCBP who are sexually active with sperm-producing persons must use contraception from C1D1 to 30 days after the last dose of venetoclax or to 6 months after the last dose of azacitidine, cladribine, or cytarabine, whichever is later in time\n\nExclusion Criteria:\n\n* Symptomatic central nervous system involvement with AML\n* Prior treatment for AML, with the exception of cytoreduction for proliferative disease (per institutional protocol) with any of the following: Hydroxyurea, hematopoietic growth factors, leukapheresis\n* Another active malignancy within the previous 5 years of C1D1\n* Investigational therapy within 28 days of C1D1, or within 5 half-lives or longer, if known\n* Recent and significant medical interventions, such as major surgery within 28 days or stem cell transplant within 100 days (and without active treatment for graft versus host disease \\[GVHD\\]) of C1D1. Standard of care procedures for patients with hematologic malignancies, such as biopsies and lumbar punctures, are not exclusionary\n* Hypersensitivity to any of the components of the investigational regimen (i.e., cladribine, cytarabine, venetoclax, azacitidine) or any excipients in the formulations\n* Treatment based on agents targeting or inhibiting BCL-2 (for other, prior indication\u002Fmalignancy) within the previous 5 years\n* History of dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally\n* Use of drugs with documented drug-drug interaction toxicities with the study drugs\n\n  * Strong or moderate CYP3A4 inducers or inhibitors within 2 days or 3 half lives whichever is longer, prior to C1D1 are exclusionary. Dose adjustments and other modifications may be considered if the wash-out period has not been met, with the approval of the investigator and the research pharmacy\n* Uncontrolled infection. Participants with controlled infection must be afebrile and hemodynamically stable for at least 72 hours prior to C1D1 and must be amenable to alternate treatment if current treatment will interact with investigational regimen\n* Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). Enrollment of individuals with evidence of chronic HBV or HCV infection will be considered on a case-by-case basis by the principal investigator\n* Individuals with serology positive for human immunodeficiency virus (HIV) and under active treatment with highly active antiretroviral therapy (HAART) (or another therapy that may interfere with metabolism of study agents)\n* Pregnancy at enrollment or unwillingness to stop breastfeeding. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding be discontinued from start of treatment until 1 week after the final dose of any study drug\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active uncontrolled infection, unstable cardiac or pulmonary function or acute insufficiency (e.g., symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia), or psychiatric illness or social situation that could limit compliance with study requirements",{"count":379,"type":22},[25],"This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling mutated AML. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as cladribine, cytarabine and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax may kill more cancer cells in patients with newly diagnosed monocytic AML and active signaling mutated AML.",[401,28],"Acute Monocytic Leukemia","2026-04-07",{"date":404,"type":34},"2026-04-13",{"date":406,"type":34},"2025-01-03",{"date":408,"type":22},"2028-05-01",{"name":40,"class":41},2,{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":42},"100632270","phase-2-y-90-radioembolization-durvalumab-tremelimumab-and-zanzalintinib-for-the-treatment-of-unresectable-and-locally-advanced-hepatocellular-carcinoma-100632270","NCT07511504","Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma","A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Durvalumab, Tremelimumab, and Zanzalintinib in Patients With Unresectable and Locally-Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Participant must provide written informed consent before any study-specific procedures or interventions are performed\n* Participants aged ≥ 18 years\n* Body weight \\> 30 kg\n* Patients must have radiologically, or histologically or cytologically confirmed hepatocellular cancer that is not amenable to transplant or resection:\n\n  * Barcelona Clinic Liver Cancer Stage B or C\n  * Cirrhosis grade of Child-Pugh (CP) A or CP-B7 (excluding albumin-bilirubin \\[ALBI\\] grade 3)\n  * Fibrolamellar and mixed hepatocellular\u002Fcholangiocarcinoma subtypes are not eligible\n* Disease must not be amenable to surgical resection, transplantation, or thermal ablation, or recurrent hepatocellular carcinoma (HCC) after a previous definitive therapy (surgery or thermoablative therapy)\n* Venous invasion (portal, hepatic, biliary) and infiltrative growth pattern are eligible\n* Eligible for Y-90 transarterial radioembolization (TARE) based on planning angiogram, with evidence of:\n\n  * ≥ 30% hepatic reserve (i.e., untreated background liver) AND\n  * Estimated lung exposure \\\u003C 30 Gy\u002F treatment (or 50 Gy cumulative total)\n* Patients with bi-lobar disease amenable to simultaneous or sequential TARE are eligible\n* Eastern Cooperative Oncology Group (ECOG) 0 - 1 at enrollment\n* Recovery to baseline or ≤ grade 1 (per Common Terminology Criteria for Adverse Events \\[CTCAE\\] version \\[v\\] 5.0) from toxicities related to any prior treatments, unless adverse events (AE\\[s\\]) are clinically non-significant and\u002For stable on supportive therapy\n* Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL) (within 14 days before first dose of study treatment)\n* White blood cell count ≥ 2500\u002FμL (within 14 days before first dose of study treatment)\n* Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL (1500\u002FμL), without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection (within 14 days before first dose of study treatment)\n* Platelet count ≥ 75 × 10\\^9\u002FL (≥ 75,000\u002FμL), without transfusion within 2 weeks of screening laboratory sample collection (within 14 days before first dose of study treatment)\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN) (within 14 days before first dose of study treatment)\n* Alkaline phosphatase (ALP) ≤ 5 x ULN (within 14 days before first dose of study treatment)\n* Total bilirubin ≤ 2 mg\u002FdL (≤ 34.2 μmol\u002FL) or \\\u003C 2 x ULN, whichever is higher (within 14 days before first dose of study treatment)\n* Serum albumin ≥ 2.8 g\u002FdL (within 14 days before first dose of study treatment)\n* International normalized ratio (INR) ≤ 1.7 x laboratory ULN (within 14 days before first dose of study treatment)\n* Stable renal function defined as serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (CrCL) ≥ 40mL\u002Fmin (≥ 0.675mL\u002Fsec) using the Cockcroft-Gault equation (within 14 days before first dose of study treatment)\n* Urine protein\u002Fcreatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol), or 24-h urine protein ≤ 1 g (within 14 days before first dose of study treatment)\n* Has at least one measurable target lesion based on modified Response Evaluation Criteria in Solid Tumors (mRECIST)\n* Participants must have at least one lesion that is amendable to biopsy\n* Participant are asked to consent to tumor biopsies for biomarker analysis of the acquired tissue at the following timepoints: pre-treatment, on-treatment (i.e., after completing the initial combination cycle of durvalumab, tremelimumab and zanzalintinib), and at time of disease progression. These biopsies are optional and are not required for study participation\n* Sexually active fertile participants and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for:\n\n  * 96 days for sperm-producing participants or\n  * 186 days for participants of child-bearing potential (POCBP) after the last dose of zanzalintinib. Additionally, sperm-producing participants must agree not to donate sperm and POCBP must agree to not donate eggs (ova, oocyte) for the purpose of reproduction during these same periods\n* POCBP must not be pregnant at screening. POCBP participants are considered to be of childbearing potential unless one of the following criteria is met:\n\n  * Documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes.\n  * Participants \\\u003C 55 years-of-age must have a serum follicle stimulating (FSH) level \\> 40 mIU\u002FmL to confirm menopause).\n\n    * Note: Documentation may include review of medical records, medical examinations, or medical history interview by study site\n\nExclusion Criteria:\n\n* Another primary tumor\n* Extrahepatic metastases\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.\n\n  * Note: Eligible participants must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment.\n  * Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed\n* Prior systemic therapy for HCC\n* Prior Y-90 radioembolization\n\n  * Note: prior transarterial chemoembolization is permitted if \\> 6 months prior to enrollment\n* Advanced liver disease with a CP-B7 (ALBI grade 3), CP-B8, CP-B9 or CP- C, or active gastrointestinal bleeding or encephalopathy or refractory ascites\n* Radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible\n* Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA4 agent, or with an agent directed to another co-inhibitory T-cell receptor (e.g., TIGIT, LAG-3, TIM-3)\n* Prior treatment with zanzalintinib, cabozantinib, or similar class of multitargeted Tyrosine Kinase Inhibitor (mTKI)\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment\n* Participants cannot be on other forms of anti-cancer therapy at the same time, except as described within this protocol\n* Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitors (e.g., rivaroxaban), or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n  * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low dose low molecular weight heparins (LMWH).\n  * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in participants without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.\n\n    * Note: participants must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer\n* Any complementary medications (e.g., herbal supplements or traditional medicines) to treat their HCC under study within 2 weeks before first dose of study treatment\n* Participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Unstable of deteriorating cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class 3 or 4, class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes).\n    * Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other clinically significant arterial thrombotic and\u002For ischemic event within 6 months before first dose of study treatment.\n    * Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before first dose of study treatment.\n\n      * Note: Participants with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.\n      * Note: Participants who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.\n    * Prior history of myocarditis\n* Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n  * Participant has evidence of tumor invading the GI tract,\n  * Active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis\n  * Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before first dose unless cause of obstruction is definitively managed and subject is asymptomatic\n  * Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.\n\n    * Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n  * Known gastric or esophageal varices that are untreated or incompletely treated with bleeding or high risk for bleeding. Participants treated with adequate endoscopic therapy (according to institutional standards) without any episodes of recurrent GI bleeding requiring transfusion or hospitalization for at least 6 months prior to study entry are eligible.\n  * Ascites, pleural effusion, or pericardial fluid requiring drainage in last 4 weeks\n* Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before start of study intervention\n* Lesions invading a major blood vessel including, but not limited to, inferior vena cava, pulmonary artery, or aorta. Participants with lesions invading the hepatic portal vasculature are eligible\n* Elevated lung shunting precluding safe treatment with Y-90 within acceptable thresholds of lung exposure, defined as \\> 30 Gy\u002Ftreatment or 50 Gy total for multiple treatments\n* Patients with future liver remnant volume \\\u003C 30% after Y-90 treatment\n* Patients in whom Y-90 is deemed unsafe due to risks of extra-pulmonary non-target embolization\n* Any deposition to the GI tract (per 99mTc-MAA SPECT-CT or Cone Beam CT)\n* Hepatic artery catheterization is contraindicated (e.g., vascular abnormalities or bleeding diathesis)\n* Severe liver dysfunction, including hepatic encephalopathy, clinically evident ascites or treatment with diuretics for ascites\n* Type Vp4 Portal vein tumor thrombosis (PVTT) involvement and lack of Tc-99m MAA deposition on the PVT per Tc-99m MAA SPECT\u002FCT\n* Participants with renal failure currently requiring dialysis of any kind are not eligible\n* Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation\n* Known allergy or hypersensitivity to any of the study drug or any of the study drug excipients\n* Other clinically significant disorders that would preclude safe study participation.\n\n  * Active infection requiring systemic treatment.\n\n    * Note: Prophylactic antimicrobial treatments (antibiotics, antimycotic, antiviral) are allowed.\n  * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness except for participants meeting all of the following criteria:\n\n    * On stable anti-retroviral therapy;\n    * CD4+ T cell count ≥ 200\u002FµL; and\n    * An undetectable viral load.\n\n      * Note: HIV testing is to be performed at screening if and as required by local regulation.\n      * Note: To be eligible, participants taking CYP inhibitors (e.g., zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose.\n      * Note: CD4+ T cell counts, and viral load are monitored per standard of care by the local health care provider\n  * Uncontrolled hepatitis B Virus (HBV) infection. Participants with controlled hepatitis B virus (HBV), defined as receiving effective antiviral therapy and adequate viral suppression (i.e., HBV deoxyribonucleic acid \\[DNA\\] ≤ 2000 IU\u002FmL) are eligible.\n\n    * Note: participants must meet liver function inclusion parameters (i.e., ALT, AST, bilirubin)\n  * Hepatitis C (HCV) infection. Participants with active, controlled HCV infection are eligible provided liver function meets eligibility criteria and are receiving management of the disease per local institutional practice.\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture.\n\n    * Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n  * Malabsorption syndrome\n  * Pharmacologically uncompensated, symptomatic hypothyroidism.\n  * Requirement for hemodialysis or peritoneal dialysis.\n  * History of solid organ or allogenic stem cell transplant\n* Major surgery (e.g., GI surgery) within 8 weeks before first dose of study treatment. Minor surgeries (e.g., simple excision) within 5 days before first dose of study treatment. Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Participant with clinically relevant ongoing complications from prior surgery are not eligible\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 470 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment. Participants with a history of additional risk factors for torsades de pointes (e.g., long QT syndrome) are also excluded \\[add reference for Fridericia formula\\].\n\n  * Note: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility\n* Any active, known or suspected autoimmune disease will be excluded, with the following exceptions:\n\n  * Type 1 diabetes mellitus.\n  * Hypothyroidism only requiring hormone replacement.\n  * Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment.\n  * Conditions not expected to recur in the absence of an external trigger\n* Known positive test for tuberculosis infection if supported by clinical or radiographic evidence of disease\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computerized tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Free thyroxine outside the laboratory normal reference range. Asymptomatic participants with free thyroxine abnormalities are eligible per investigator's discretion\n* Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days before first dose of study treatment. Note the following exceptions:\n\n  * Inhaled, intranasal, intra-articular, or topical steroids are permitted.\n  * Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.\n  * Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is permitted\n* Prior allogeneic stem cell or solid organ transplantation\n* Receipt of a live, attenuated vaccine within 30 days prior to enrollment\n* Documented hepatic encephalopathy within 6 months before first dose of study treatment\n* Clinically meaningful ascites (i.e., ascites requiring paracentesis or escalation in diuretics) within 6 months before first dose of study treatment\n* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, safety of participation, or interpretation of results. This includes significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome) or any other serious medical condition or abnormality in clinical laboratory tests that meet these criteria in the investigator's opinion\n* Patient is pregnant or lactating\n* Inability to swallow tablets or ingest a suspension either orally or by a nasogastric (NG) or gastrostomy (PEG) tube, or unwillingness or inability to receive IV administration\n* Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 2 years prior to first dose of study treatment that requires active treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6\n* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent\n* Participants with any condition that, in the opinion of the investigator, could jeopardize the participant's safety or adherence to the study protocol",{"count":379,"type":22},[25],"This phase II trial tests how well giving Y-90 radioembolization, durvalumab, tremelimumab and zanzalintinib works for the treatment of hepatocellular carcinoma that cannot be removed by surgery (unresectable) and that has spread to nearby tissue or lymph nodes (locally advanced). Y-90 radioembolization is a therapy that injects radioactive particles directly into an artery that feeds liver tumors to cut off their blood supply. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Zanzalintinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving Y-90 radioembolization, durvalumab, tremelimumab and zanzalintinib may be effective for treating unresectable and locally-advanced hepatocellular carcinoma.",[422,201,204,423],"Locally Advanced Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma","2026-03-30",{"date":426,"type":34},"2026-04-06",{"date":428,"type":22},"2026-04-02",{"date":430,"type":22},"2027-08-01",{"name":40,"class":41},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":439,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":42},"100542406","create-art-for-children-with-cancer-100542406","NCT06342453","CREATE: Art for Children With Cancer","CREATE: Clinical Research Examining the Arts as Targeted Elements in Childhood Cancer Care","Inclusion Criteria:\n\n* Aged 8 to 13 years of age\n* Have been diagnosed with cancer of any type in the prior 12 months\n* Be English literate (we will amend this criterium when the study surveys are validated in Spanish). Parent\u002Fcaregiver of child participant may be Spanish speaking\n* Physically and cognitively able to participate in creative arts\n* Expected to receive enough treatment at local site to participate in all four intervention sessions\n\nExclusion Criteria:\n\n* Not English literate\n* Otherwise unable to complete study procedures","8 Years","13 Years",{"count":442,"type":22},72,[98],"This clinical trial is being done to develop and test how well creative arts interventions (drawing, painting, making sculptures) compared to watching videos can affect symptoms and impact the quality of life in children with cancer. Creative arts mind-body interventions (CrA) are one type of complementary health interventions which have been associated with improved quality of life and reduced symptom burden among children with cancer. CrA is an ideal intervention for children with cancer due to the long hours spent in the hospital setting for treatments, the creativity and developmental focus of children, and their potential ability to communicate more easily through art than words. Researchers want to develop and test a CrA intervention to help improve symptoms and the quality of life of children with cancer.",[77,272],"2026-03-25",{"date":424,"type":34},{"date":449,"type":34},"2024-06-04",{"date":451,"type":22},"2026-12-31",{"name":40,"class":41},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":42},"100631272","phase-2-safety-and-efficacy-of-a-single-dose-of-gruticibart-to-prevent-crt-100631272","NCT07498517","Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT","A Study to Evaluate the Safety and Efficacy of a Single Dose of Gruticibart for the Prevention of Early Catheter-related Thrombosis","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Men and women, aged ≥ 18 years.\n* In consultation with PI and treating physician, participant's therapy allows for a 1 to 2-day period between administration of study drug and subsequent start of planned therapy.\n* Individuals that will undergo insertion of a CVC as part of planned therapy per institutional standards.\n* Must have ECOG performance status ≤ 2 (refer to Appendix A).\n* At time of enrollment, must have:\n\n  * Platelet count \\> 50 x 109\u002FL\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test during screening and at check-in Day -1. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Participants of childbearing potential are defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal.\n* Female participants of childbearing potential must agree to use two forms of highly effective contraception (Appendix B) starting with the first dose of study therapy through 90 days after the last dose of study therapy.\n\nParticipants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\>1 year without an alternative medical cause.\n\n* Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy.\n\nExclusion Criteria:\n\n* Concurrent enrollment in another therapeutic clinical trial\n* Active leukemia (lymphoma and myeloma may be included)\n* Primary brain tumors or known brain metastases\n* Active infection and\u002For current use of an oral antibiotic\n* At time of enrollment:\n\n  * Deranged baseline clotting, where INR \\> 1.5\n  * Known bleeding diathesis\n  * Use of anticoagulation, either therapeutic or prophylactic, for any indication at enrollment\n* -At the discretion of the investigator, any other contraindication to anticoagulation therapy\n* Previously documented hypersensitivity to either the drug or excipients.\n* Psychiatric illness\u002Fsocial situations, or any other condition, that in the opinion of the investigator, would limit compliance with study requirements.\n* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 90 days after study drug administration.",{"count":298,"type":22},[25],"This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.",[464],"Thrombosis","2026-03-23",{"date":467,"type":34},"2026-03-27",{"date":469,"type":22},"2026-02-28",{"date":471,"type":22},"2029-10-02",{"name":40,"class":41},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":42},"100599857","early-phase-1-omo-103-for-the-treatment-of-locally-advanced-or-metastatic-pancreatic-ductal-adenocarcinoma-100599857","NCT07089940","OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma","An Early Phase 1 Trial to Assess Pharmacodynamic Effects of OMO-103 in Patients With Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Must provide written informed consent before any study-specific procedures or interventions are performed\n* Must be ≥ 18 years old at the time of informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Clinically-confirmed diagnosis of locally-advanced or metastatic adenocarcinoma of the pancreas\n\n  * Participants may be treatment naïve or have received prior therapy for the treatment of their PDAC. A minimum washout period of 14-days after completing the most recent line of therapy is required before a participant can initiate treatment with study agent(s)\n* Based on available imaging, participant must have at least one disease lesion that can be biopsied in accordance with institutional standards\n* Patient agrees to undergo a minimum of 2 biopsies (pre- and post-treatment). Note: at principal investigator (PI) discretion, archival sample may be obtained in lieu of pre-treatment biopsy\n* Hemoglobin ≥ 7.5 g\u002FdL\n* Absolute neutrophil count (ANC) ≥ 1.0 x 10\\^9\u002FL (\\> 1500 per mm\\^3)\n* Platelet count ≥ 75 x 10\\^9\u002FL (\\> 100,000 per mm\\^3)\n* Calculated creatinine clearance \\> 50 mL\u002Fmin\u002F1.73m\\^2 (per Cockcroft-Gault equation)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT): ≤ 3 x upper limit of normal (ULN), or ≤ 5 x ULN in presence of liver metastases\n* Participants of childbearing potential (POCBP) must agree to abstain from sexual intercourse or use effective methods of contraception starting with the first dose of study therapy through 6 months from the last dose of study intervention\n* POCBP may participate provided they have a negative serum pregnancy test at screening and a negative serum OR urine pregnancy test within 7 days of starting treatment\n* Sperm-producing participants must agree to abstain from sexual intercourse or use effective contraception starting with the first dose through 6 months after last dose of study intervention\n\nExclusion Criteria:\n\n* Concomitant use of other anti-cancer therapy otherwise not permitted in this protocol, including: chemotherapy, immunotherapy, hormonal therapy (hormone replacement therapy is acceptable), radiotherapy (except for palliative), biological therapy, or other novel agent\n* Prior anti-cancer therapy within 2 weeks prior to study enrollment\n* Prior treatment with a MYC inhibitor\n* Known severe hypersensitivity to OMO-103 or to any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition\n* Major surgery within 6 weeks prior to enrollment\n* Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3 months of initiating study intervention\n* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent\n* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements",{"count":481,"type":22},12,[483],"EARLY_PHASE1","This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). OMO-103 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial may help researchers determine how exposure to OMO-103 changes pancreatic tumor cells.",[486,487,164,165,488],"Locally Advanced Pancreatic Ductal Adenocarcinoma","Metastatic Pancreatic Ductal Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8","2026-03-19",{"date":465,"type":34},{"date":492,"type":34},"2026-01-27",{"date":84,"type":22},{"name":40,"class":41},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":42},"100362937","early-phase-1-targeted-pathway-inhibition-in-patients-with-pancreatic-cancer-100362937","NCT04005690","Targeted Pathway Inhibition in Patients With Pancreatic Cancer","A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document\n* Age \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Clinically-confirmed diagnosis of resectable, borderline resectable, locally-advanced or metastatic adenocarcinoma of the pancreas.\n\n  * Patients with disease that is eligible for curative surgery may not be eligible for all study arms.\n  * Participants may be treatment naïve or have received prior therapy for the treatment of their pancreatic ductal adenocarcinoma (PDAC). A minimum washout period of 10-days after completing the most recent line of therapy is required before a participant can initiate treatment with study agent(s)\n* Based on available imaging, participant must have at least one disease lesion that can be biopsied in accordance with institutional standards\n* Hemoglobin \\>= 9.0 g\u002FdL with no blood transfusion within 28 days of starting treatment (within 4 weeks prior to initiating window treatment). Note: laboratory tests performed after initial screening (but still within the screening window) will be evaluated by the investigator; should any of these values fall outside eligibility parameters, the patient may still be eligible per investigator discretion\n* White blood cells (WBC) \\> 3 x 10\\^9\u002FL (within 4 weeks prior to initiating window treatment). Note: laboratory tests performed after initial screening (but still within the screening window) will be evaluated by the investigator; should any of these values fall outside eligibility parameters, the patient may still be eligible per investigator discretion\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL (\\> 1500 per mm\\^3) (within 4 weeks prior to initiating window treatment). Note: laboratory tests performed after initial screening (but still within the screening window) will be evaluated by the investigator; should any of these values fall outside eligibility parameters, the patient may still be eligible per investigator discretion.\n\n  * May be waived on a case-by-case basis for patient populations recognized to have normal baseline values below this level\n* Platelet count \\>= 100 x 10\\^9\u002FL (\\> 100,000 per mm\\^3) (within 4 weeks prior to initiating window treatment). Note: laboratory tests performed after initial screening (but still within the screening window) will be evaluated by the investigator; should any of these values fall outside eligibility parameters, the patient may still be eligible per investigator discretion\n* Creatinine =\\\u003C 1.5 x upper limit of normal (ULN), OR measured or calculated creatinine clearance (glomerular filtration rate \\[GFR\\] can also be used in place of creatinine or creatinine clearance \\[CrCl\\]) \\>= 60 mL\u002Fmin\u002F1.73m\\^2 for participants with creatinine levels \\> 1.5 x institutional ULN (within 4 weeks prior to initiating window treatment). Note: laboratory tests performed after initial screening (but still within the screening window) will be evaluated by the investigator; should any of these values fall outside eligibility parameters, the patient may still be eligible per investigator discretion.\n\n  * Creatinine clearance should be calculated per institutional standard. For participants with a baseline calculated creatinine clearance below normal institutional laboratory values, a measured baseline creatinine clearance should be determined. Individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis\n* Serum bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN) (within 4 weeks prior to initiating window treatment). Note: laboratory tests performed after initial screening (but still within the screening window) will be evaluated by the investigator; should any of these values fall outside eligibility parameters, the patient may still be eligible per investigator discretion\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 2.5 x ULN (within 4 weeks prior to initiating window treatment). Note: laboratory tests performed after initial screening (but still within the screening window) will be evaluated by the investigator; should any of these values fall outside eligibility parameters, the patient may still be eligible per investigator discretion\n* Participants must be willing to undergo mandatory on-study tumor biopsies\n* Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n* Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible\n* Participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Participants must agree to use an adequate method of contraception starting with the first dose of study therapy and for the required length of time ascribed to the assigned study drug assignment\n* No other prior invasive malignancy is allowed except for the following: adequately treated basal (or squamous cell) skin cancer, in situ breast or cervical cancer, any malignancy treated with a curative intent without evidence of disease recurrence for at least 6 months\n* Individuals must not have known active hepatitis B virus (HBV). Those who have completed curative therapy for hepatitis C virus (HCV) are eligible. HCV infection permitted but patient must be Child's Pugh A. Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following 3 criteria:\n\n  * CD4 counts \\>= 350 mm\\^3\n  * Serum HIV viral load of \\\u003C 25,000 IU\u002Fml and\n  * Treated on a stable antiretroviral regimen\n  * Note: HIV testing is not required at screening, unless if required by local regulations, where the testing will be done by local laboratory\n* AZENOSERTIB SPECIFIC CRITERIA: Those with prior treatment with a WEE1 inhibitor are not eligible\n* AZENOSERTIB SPECIFIC CRITERIA: Patients are not eligible if any of the following treatment interventions have occurred within the specified time frame(s) prior to starting study intervention:\n\n  * Major surgery within 28 days (the surgical incision should be fully healed prior to study drug administration)\n  * Radiation therapy within 21 days; however, if the radiation portal covered ≤ 5% of the bone marrow reserve, the subject is eligible irrespective of the end date of radiotherapy\n  * Autologous or allogeneic stem cell transplant within 3 months\n  * Current use of an investigational agent that is not expected to be cleared by the first dosing of study drug or that has demonstrated to have prolonged side effects\n  * Prescription, non-prescription drugs or food known as moderate to strong inducers of CYP3A within 2 weeks\n* AZENOSERTIB SPECIFIC CRITERIA: Patients are not eligible if there is a serious illness or medical condition(s) including, but not limited to, the following:\n\n  * Symptomatic brain metastases\n  * Leptomeningeal disease that requires or is anticipated to require immediate treatment.\n  * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the subject inappropriate for entry into this study\n  * Significant gastrointestinal abnormalities, including an inability to take oral medication, requirement for IV alimentation, active peptic ulcer, chronic diarrhea or vomiting considered to be clinically significant in the judgment of the Investigator, or prior surgical procedures affecting absorption\n  * Active or uncontrolled infection. Subjects with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥ 72 hours\n* AZENOSERTIB SPECIFIC CRITERIA: 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of \\>480 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid\n* AZENOSERTIB SPECIFIC CRITERIA: History or current evidence of congenital or family history of long QT syndrome or Torsade de Pointes\n* AZENOSERTIB SPECIFIC CRITERIA: Patients are not eligible in cases of unresolved toxicity of grade \\> 1 attributed to any prior therapies (excluding grade 2 neuropathy, alopecia or skin pigmentation)\n* AZENOSERTIB SPECIFIC CRITERIA: Patients are not eligible if there is known hypersensitivity to any drugs similar to ZN-c3 in class\n* AZENOSERTIB SPECIFIC CRITERIA: Individuals that are pregnant or breast-feeding are not eligible\n* AZENOSERTIB SPECIFIC CRITERIA: Participants must agree to use an adequate method of contraception as follows:\n\n  * Participants of childbearing potential agree to use adequate methods of contraception for the duration of study participation.\n  * Sperm-producing participants must agree to refrain from sperm donation during the study and for 30 days after the last dose of study drug\n* AZENOSERTIB SPECIFIC CRITERIA: Participant requiring any medications that can lead to significant QT prolongation are not eligible\n* AZENOSERTIB SPECIFIC CRITERIA: Participant requires administration of strong and moderate CYP3A4 inhibitors and inducers as well as strong and moderate P-glycoprotein (P-gp) inhibitors are not eligible\n* AZENOSERTIB SPECIFIC CRITERIA: Due to potential CYP3A4 interaction with the study medication, participants are asked to refrain from consumption of seville oranges, grapefruit or grapefruit juice, ppomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices) from 7 days prior to the initiating study agent and during the entire study. NOTE: Orange juice is permitted\n* AZD5305 SPECIFIC CRITERIA: Participants must agree to use an adequate method of contraception as follows:\n\n  * Participants of childbearing potential must agree to use adequate methods of contraception starting with the first dose of study therapy through at least 6 months after the last dose of study therapy\n  * Sperm-producing participants must use a condom during treatment and for 6 months after the last dose of AZD5305 when having sexual intercourse with an individual that is pregnant or of childbearing potential. Individuals that are partners of sperm-producing participants should also use a highly effective form of contraception if they are of childbearing potential\n* TREMELIMUMAB SPECIFIC CRITERIA: Participants of childbearing potential must agree to use adequate methods of contraception starting with the first dose of study therapy through at least 3 months after the last dose of study therapy\n\nExclusion Criteria:\n\n* Tumor not accessible for core biopsy\n* Medical co-morbidities that are deemed to make risk of surgery unacceptably high as determined by institutional standards\n* Recent major surgery within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Patients must be recovered from effects of surgery\n* Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil)\n* Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil)\n* Concomitant use of other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy (hormone replacement therapy is acceptable), radiotherapy (except for palliative), biological therapy or other novel agent) or live virus and live bacterial vaccines while the patient is receiving study medication. Strong or moderate CYP3A inhibitors and inducers should not be taken with study treatment; however, if no other suitable alternative concomitant medication is available, dose reductions may be allowed under careful monitoring\n* Known severe hypersensitivity to the study agent(s) (or equivalent agents, respectively), or any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent(s)\n* Clinically significant cardiac disease or impaired cardiac function, including any of the following:\n\n  * Clinically significant and\u002For uncontrolled heart disease such as congestive heart failure (New York Heart Association grade \\>= 2) uncontrolled hypertension, or clinically significant arrhythmia currently requiring medical treatment\n  * Corrected QT using Fridericia's formula (QTcF) \\> 470 msec for females, or \\> 450 msec for males, on screening electrocardiogram (ECG) or congenital long QT syndrome\n  * Acute myocardial infarction or unstable angina pectoris \\\u003C 6 months prior to screening\n* Clinically significant cardiac disease or impaired cardiac function\n* Female participant who is pregnant or lactating\n* Participant is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally\n* Participant has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and\u002For other treatment)\n* Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Participants with a history of hypersensitivity reactions to study agents or their excipients\n* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through at least 120 days after the last dose of trial treatment\n* AZD5305 SPECIFIC CRITERIA: Known allergy or hypersensitivity to AZD5305 or any of its excipients\n* AZD5305 SPECIFIC CRITERIA: Patients with myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML\n* AZD5305 SPECIFIC CRITERIA: Cardiovascular disease, QTc \\> 450 ms, or any factors that increase the risk of QTc prolongation or risk of arrhythmic events\n* AZD5305 SPECIFIC CRITERIA: History of persisting (\\> 2 weeks) severe pancytopenia due to any cause (ANC \\\u003C 0.5 x 10\\^9\u002FL or platelets \\\u003C 50 x 10\\^9\u002FL)\n* TREMELIMUMAB SPECIFIC CRITERIA: Medical co-morbidities that are deemed to make risk of surgery unacceptably high as determined by institutional standards\n* TREMELIMUMAB SPECIFIC CRITERIA: Participants have received prior immunotherapy for the treatment of their PDAC\n* TREMELIMUMAB SPECIFIC CRITERIA: Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) \\> grade 2 from prior neoadjuvant therapy\n* TREMELIMUMAB SPECIFIC CRITERIA: History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, interstitial lung disease (ILD), pleural effusion, or pulmonary fibrosis diagnosed in the past 6 months prior to randomization\n* TREMELIMUMAB SPECIFIC CRITERIA: Active or prior documented autoimmune or inflammatory disorders",{"count":298,"type":22},[483],"This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic cancer.",[486,487,164,165,488,506,507,508],"Unresectable Pancreatic Ductal Adenocarcinoma","Borderline Resectable Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma","2026-02-26",{"date":511,"type":34},"2026-02-27",{"date":513,"type":34},"2019-08-01",{"date":515,"type":22},"2028-02-01",{"name":40,"class":41},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":524,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":42},"100306502","phase-2-gadolinium-and-ferumoxytol-mri-in-diagnosing-patients-with-abnormalities-in-the-central-nervous-system-100306502","NCT03270059","Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System","The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS","Inclusion Criteria:\n\n* Subjects must have one of the following:\n\n  * Neurological findings (i.e. headache, loss of consciousness, paresis, cranial neuropathy, seizures, etc.)\n  * Radiological abnormalities in the brain (neoplastic or non-neoplastic in nature)\n  * Neoplastic process elsewhere in the body that may affect the brain (i.e. possible metastasis, vascular compromise, treatment related changes, etc.)\n* Subjects must be able to undergo MRI imaging without anesthesia\n* Subjects must be at least 10 years of age\n* All subjects, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines\n* Sexually active women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; surgical intervention i.e. tubal ligation or vasectomy; post-menopausal \\\u003C 6 months; or abstinence) for at least two months after each cycle of the study; should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n\nExclusion Criteria:\n\n* Subjects with clinically significant signs of uncal herniation, such as acute pupillary enlargement, rapidly developing motor changes (over hours), or rapidly decreasing level of consciousness, are not eligible\n* Subjects with known allergic or hypersensitivity reactions to parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations (Ferumoxytol Investigator's Drug Brochure, 2009); subjects with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion\n* Subjects who are pregnant or lactating or who suspect they might be pregnant\n* Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, or have an allergy to gadolinium containing contrast material\n* Subjects with known iron overload (genetic hemochromatosis); in subjects with a family history of hemochromatosis, hemochromatosis must be ruled out prior to study entry with normal values of the following blood tests: transferrin saturation (TS) test and serum ferritin (SF) test; all associated costs will be paid by the study\n* Subject who have received ferumoxytol within 3 weeks of study entry\n* Subjects with three or more drug allergies from separate drug classes","10 Years",{"count":268,"type":22},[25],"This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.",[529,530,531],"Central Nervous System Neoplasm","Cranial Nerve Disorder","Metastatic Malignant Neoplasm in the Brain","2026-02-25",{"date":511,"type":34},{"date":535,"type":34},"2017-10-06",{"date":537,"type":22},"2028-12-15",{"name":40,"class":41},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":546,"minAge":18,"maxAge":547,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":554,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":559,"leadSponsor":560,"locationsCount":42},"100626322","phase-2-mammogram-pretreatment-with-ulipristal-acetate-100626322","NCT07434128","Mammogram Pretreatment With Ulipristal Acetate","Progesterone Receptor Modulator Mammogram Pretreatment for Premenopausal People With a History of Extremely Dense Breast Tissue","Inclusion Criteria:\n\n* Participant or legally authorized representative (LAR) must provide written informed consent before any study-specific procedures or interventions are performed\n* Ages 18-50 years. The maximum age cut off is due to the intervention only applying to premenopausal physiology only\n* Assigned female at birth with at least one ovary in situ. Members of all races and ethnic groups will be included\n* Presenting for a screening mammogram\n* Has an antecedent mammogram within 24 months with a Breast Imaging Reporting and Data System (BI-RADS) breast composition score of Category D (extremely dense) for which images are available for analysis\n* Report no history of breast cancer or symptoms concerning for breast cancer such as a self-palpated mass\n* Reasonably assumed to be premenopausal by history of regular menses. For individuals who do not menstruate (due to hysterectomy or endometrial ablation), premenopausal status will be determined clinically by the absence of symptoms of menopause including weekly hot flashes which is consistent with clinical care\n\nExclusion Criteria:\n\n* Having a mammogram as part of a diagnostic process\n* Current breast implants in one or both breasts\n* Pregnant, less than 1 year postpartum or breastfeeding within last 6 months at the time of their antecedent mammogram or their current mammogram. This exclusion is due to known changes in mammograms during pregnancy and postpartum that would preclude comparative analyses\n* Using hormonal medications including estrogens or progestins\n* History of allergy to UPA\n* A history of liver disease (including but not limited to viral or autoimmune hepatitis, non-alcoholic fatty liver disease, hemochromatosis or Wilson's disease), alcoholism or a history of liver function tests such as aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) greater than 3 x the upper limit of normal without known etiology\n* Attempting pregnancy during the study duration or a positive urine pregnancy for people at risk of pregnancy who cannot be reasonably assumed not to be pregnant at the beginning of the intervention\n* Use of CYP3A4 inducer or inhibitors which may alter plasma concentrations of study drug (See Appendix A for list of common drugs\u002Fherbs). Regarding recent use of CYP3A4 inducers or inhibitors, a washout period will be deemed sufficient if at least 14 days or 5 half lives of the drug have elapsed prior to initiation of the study drug, whichever is longer. Participants will be advised to abstain from CYP3A4 inducers or inhibitors during the study and will only be ineligible if unable to","FEMALE","50 Years",{"count":73,"type":22},[25],"This phase II trial tests whether taking ulipristal acetate prior to a mammogram decreases breast density for people with a history of extremely dense breast tissue. One limitation to breast cancer screening with mammography is dense breast tissue, which decreases the sensitivity of screening as breast density masks cancer and precancerous lesions. Ulipristal acetate lowers the amount of progesterone made by the body which may temporarily decrease the density of the breast tissue, allowing for a more accurate mammogram for people with extremely dense breast tissue.",[552,553],"Mammography Screening","Breast Density",[555],"Progesterone receptor modulators","2026-02-21",{"date":532,"type":34},{"date":428,"type":22},{"date":84,"type":22},{"name":40,"class":41},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":580,"locationsCount":42},"100614349","an-exercise-intervention-for-improving-mental-and-physical-health-in-patients-with-primary-brain-tumors-and-their-caregivers-et-neuro-trial-100614349","NCT07278440","An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregivers, ET-NEURO Trial","ET-NEURO: A Pilot Trial of the Exercise Together Program in Primary Brain Tumor Patient-Caregiver Dyads Incorporating Glymphatic MRI","Inclusion Criteria:\n\n* PATIENT INCLUSION:\n* Patient participants must have a histologically confirmed diagnosis of World Health Organization (WHO) grade 1-4 PBT such as glioblastoma, astrocytoma, oligodendroglioma, ependymoma, medulloblastoma, meningioma, and other primary brain tumors. Confirmed by review of the electronic medical record (EMR) and subsequently recorded in health history questionnaire. In cases where the EMR isn't clear, their Oregon Health \\& Science University OHSU provider will be contacted for confirmation\n* Patient participants on active oral chemotherapy, including cytotoxic chemotherapy and molecularly targeted therapy, for the treatment of PBT are allowed\n* Patient participants must be at least 6 weeks after the last dose of intravenous infusion chemotherapy for the treatment of PBT, including bevacizumab, prior to enrollment\n* Patient participants must be at least 6 weeks post-radiation for PBT prior to enrollment. Patient participants must be at least 8 weeks post-craniotomy prior to enrollment\n* Patient participants must have a co-residing spouse or partner caregiver due to the program's focus on intimacy\n* Patient participants must have a Karnofsky performance score of at least 70 or an Eastern Cooperative Oncology Group (ECOG) score of 1 or less\n* Patient participants are permitted to participate in other therapeutic interventional clinical trials for PBT\n* PATIENT AND CAREGIVER INCLUSION:\n* Patient participants and caregiver participants must be 18 years of age or older\n* Patient participants and caregiver participants must state willingness to comply with all study procedures and availability for the duration of the study\n* Patient participants and caregiver participants must have the ability to understand and the willingness to sign a written informed consent document\n* Patient participants and caregiver participants must have home internet sufficient for videoconferencing\n\nExclusion Criteria:\n\n* PATIENT AND CAREGIVER EXCLUSION:\n* Patient and caregiver participants must not have engaged in two or more regular strength training sessions per week (e.g., physical therapy) during the past 30 days, as confirmed by self-report on the health history questionnaire\n* Patient participants and caregiver participants with cognitive difficulties preclude answering survey questions. In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the principal investigator\n* Because this exercise intervention has not been evaluated in pregnant populations and the study team cannot provide the enhanced monitoring needed to ensure maternal and fetal safety, participants who are pregnant or planning pregnancy are excluded\n* Patient participants and caregiver participants with medical condition, movement condition, pre-existing focal neurological deficits, new focal deficits concerning for recurrent or progressive PBT necessitating second line treatment, post operative deficits\u002Fwound, or medication use that contraindicates participation in moderate intensity exercise. Specific contraindications include the following: poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate without a walker or wheelchair, inability to stand for 3 minutes, severe hearing or vision problem\n\n  * Confirmed by a combination of reviewing the EMR, self-report on the health history questionnaire, and\u002For by physician clearance. All patient participants will receive physician clearance by the neuro-oncology investigators prior to participating in the trial. For caregiver participants: must answer 'No' to American College of Sports Medicine pre-participation screening questions. If caregiver participants answer 'Yes' to either question they may be required to obtain physician clearance prior to being considered eligible. Physician clearance may also be requested at the discretion of the principal investigator",{"count":569,"type":22},36,[98],"This clinical trial evaluates the effects of a partnered exercise program, called Exercise Together, on participants with primary brain tumors and their caregivers. Standard treatments for primary brain tumors require extensive caregiver support, and both patients and caregivers experience high psychological distress and physical burden as a result. While exercise is known to improve outcomes in cancer patients, its impact on primary brain tumor patients and caregivers remains unstudied. Exercise Together is a supervised, group exercise program previously studied in patients with other types of cancer, though never in patients with primary brain tumors or their caregivers. Exercise Together uses functional resistance training to target muscle groups essential for everyday activities to improve daily functioning. Since exercises are done in a partnered format, Exercise Together is also designed to foster teamwork and strengthen the relationship between the patient and their caregiver. This program may be safe, feasible, and effective in improving the mental and physical health of primary brain tumor patients and their caregivers.",[573],"Primary Brain Neoplasm","2026-02-11",{"date":576,"type":34},"2026-02-13",{"date":469,"type":22},{"date":579,"type":22},"2026-08-02",{"name":40,"class":41},""]